 
CLINICAL STUDY PROTO COL  
GBT440 -006 
Study Number  GBT440 -006 
Study Title  A Phase II randomized,  placebo -controlled study of GBT440 to 
evaluate the safety, tolerability, pharmacokinetics and effect on 
hypoxemia in subjects  with Idiopathic Pulmonary Fibrosis  (IPF) 
Investigational Product  GBT440  
IND Number  128319  
Sponsor  400 East Jamie Court, Suite 101  
South San Francisco,  
CA 94080  
United States of America  
Sponsor’s Medical 
Director  Nicholas  Vlahakis, M.D.  
Senior Medical Director  
Global Blood Therapeutics  
400 East Jamie Court, Suite 101  
South San Francisco, CA 94080  
(650) 741-7730  (Office Telephone No.)  
nvlahakis@globalbloodtx.com  
Medical Monitor  Toni Bransford, M.D.  
Senior Medical Director  
Worldwide Clinical Trials  
973-420-6236  
toni.bransford@worldwide.com  
Version / Date  Amendment  3, 21 December , 2016  
CONFIDENTIAL  
The information in this study protocol is strictly confidential and is available for review to 
Investigators, study center personnel, the ethics committee and the health authorities.  It will 
not be disclosed to third parties without written authorization from the Sponsor, except to 
obtain informed consent from persons receiving the study treatment.  Once the protocol is 
signed, its terms are binding for all parties.  
 

Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 3 
 
CONFIDENTIAL  
 INVESTIGATOR STATEMENT OF APPROVAL AND COMPLIANCE  
A Phase I I randomized, placebo -controlled study of GBT440 to evaluate the safety, 
tolerability, pharmacokinetics and effect on hypoxemia in subjects with Idiopathic 
Pulmonary Fibrosis (IPF)  
Protocol Number: GBT440 -006, Amendment 3 
APPROVAL  
The signature of the Investigator below constitutes approval of this protocol  as written and 
reflects the Investigator’s commitment to conduct the study in accordance with the protocol, 
the applicable laws and regulations  and in compliance with  ICH Good Clinical Practice 
guidelines.  
 
Principal Investigator:   
Date:   
Title:   
 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 4 
 
CONFIDENTIAL  
 SPONSOR CONTACT INFOR MATION  
 
Sponsor’s Medical Director  Nicholas  Vlahakis, M.D.  
Senior Medical Director  
(650) 741-7730   
nvlahakis@globalbloodtx.com  
Clinical Trial Manager  Aimee Enriquez  
Clinical Trial Manager  
(650) 741-7777   
aenriquez@globalbloodtx.com  
Clinical Operations Oversight  Bella Oguno, M .P.H. 
Director, Clinical Operations  
 (650) 351 -4758  
boguno@globalbloodtx.com  
 
 
  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 5 
 
CONFIDENTIAL  
 TABLE OF CONTENTS  
CLINICAL  STUDY PROTOCOL  ................................ ................................ ............................ 1 
GBT440 -006 ................................ ................................ ................................ .............................. 1 
SPONSOR CONTACT INFO RMATION  ................................ ................................ ................. 4 
TABLE OF CONTENTS  ................................ ................................ ................................ ........... 5 
LIST OF TABLES  ................................ ................................ ................................ ..................... 9 
LIST OF APPENDICES  ................................ ................................ ................................ ............ 9 
LIST OF ABBREVIATION S ................................ ................................ ................................ ..10 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ........ 13 
1. INTRODU CTION  ................................ ................................ ................................ 21 
1.1. Disease Background  ................................ ................................ ............................. 21 
1.2. GBT440  ................................ ................................ ................................ ................ 21 
1.3. Rationale for Study  ................................ ................................ ............................... 22 
1.4. Nonclinical Data  ................................ ................................ ................................ ...22 
1.4.1.  Nonclinical Pharmacology  ................................ ................................ .................... 23 
1.4.2.  Safety Pharmacology  ................................ ................................ ............................ 23 
1.4.3.  Pharmacokinetics  ................................ ................................ ................................ ..23 
1.4.4.  Metabolism and Potential Drug Interactions  ................................ ........................ 24 
1.4.5.  Toxicology  ................................ ................................ ................................ ............ 24 
1.5. Clinical Development of GBT440  ................................ ................................ ........ 24 
1.5.1.  Safety Findings in Study GBT440 -001 ................................ ................................ 25 
1.5.2.  Pharmacokinetic Parameters  ................................ ................................ ................. 25 
1.5.3.  Dose Rationale  ................................ ................................ ................................ ......26 
1.5.4.  Potential Risk of GBT440 Treatment  ................................ ................................ ...26 
1.5.5.  Conclusions Based on Clinical Study Data  ................................ .......................... 27 
2. STUDY OBJECTIVES  ................................ ................................ ........................ 28 
2.1. Primary Objective  ................................ ................................ ................................ .28 
2.2. Secondary Objectives  ................................ ................................ ........................... 28 
2.3. Exploratory Objectives  ................................ ................................ ......................... 28 
3. INVESTIGATIONAL PLAN  ................................ ................................ ............... 29 
3.1. Study Design  ................................ ................................ ................................ ......... 29 
3.2. Endpoints  ................................ ................................ ................................ .............. 32 
3.2.1.  Primary  Endpoint  ................................ ................................ ................................ ..32 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 6 
 
CONFIDENTIAL  
 3.2.2.  Secondary Endpoints  ................................ ................................ ............................ 32 
3.2.3.  Exploratory Endpoints  ................................ ................................ .......................... 32 
4. STUDY POPULATION  ................................ ................................ ....................... 33 
4.1. Inclusion Criteria  ................................ ................................ ................................ ..33 
4.2. Exclusion Criteria  ................................ ................................ ................................ .33 
5. STUDY PROCEDURES AND  EVALUATIONS  ................................ ............... 36 
5.1. Subject Screening  ................................ ................................ ................................ .36 
5.2. Avoidance of Pregnancy  ................................ ................................ ....................... 36 
5.3. Clinical Assessments  ................................ ................................ ............................ 37 
5.3.1.  Medical History and Demographic Data  ................................ .............................. 37 
5.3.2.  Physical Examination  ................................ ................................ ........................... 37 
5.4. Laboratory Examination  ................................ ................................ ....................... 37 
5.4.1.  Clinical Laboratory Studies  ................................ ................................ .................. 37 
5.5. Disease Related Evaluations  ................................ ................................ ................. 39 
5.5.1.  Spirometry and Diffus ing Capacity of the Lung for Carbon Monoxide (DL CO) ..39 
5.5.2.  Oxygen Saturation  ................................ ................................ ................................ 39 
5.5.3.  6-Minute Walk Test (6MWT)  ................................ ................................ .............. 39 
5.5.4.  Cardiopulmonary Exercise Testing (CPET)  ................................ ......................... 40 
5.5.5.  Patient Reported Outcome (PRO) Measures  ................................ ........................ 40 
5.6. Pharmacokinetic Samples  ................................ ................................ ..................... 42 
6. EARLY DISCONTINUATIO N OF STUDY OR INDIVI DUAL SUBJECTS  ...43 
6.1. Early Discontinuation of the Study and/or Site  ................................ .................... 43 
6.2. Early Discontinuation of Individual subjects  ................................ ....................... 43 
6.3. Study Treatment Discontinuation  ................................ ................................ ......... 43 
7. STUDY DRUG AND ACCOU NTABILITY  ................................ ....................... 45 
7.1. Study Drug  ................................ ................................ ................................ ............ 45 
7.1.1.  Physi cal Description  ................................ ................................ ............................. 45 
7.1.2.  Formulation  ................................ ................................ ................................ ........... 45 
7.1.3.  Packaging and Labeling  ................................ ................................ ........................ 45 
7.1.4.  Supply  ................................ ................................ ................................ ................... 45 
7.1.5.  Storage and Handling Procedure  ................................ ................................ .......... 45 
7.2. Drug Accountability  ................................ ................................ ............................. 46 
8. DOSAGE AND TREATMENT  ADMINISTRATION  ................................ ........ 47 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 7 
 
CONFIDENTIAL  
 8.1. Treatment Regimen  ................................ ................................ .............................. 47 
8.2. Study Drug Dispensing  ................................ ................................ ......................... 47 
8.3. Dose Modification  ................................ ................................ ................................ 47 
8.3.1.  Dose Adjustment  ................................ ................................ ................................ ..48 
8.3.2.  Dose Interruption  ................................ ................................ ................................ ..48 
8.3.3.  Pirfenidone or Nintedanib Background Therapy  ................................ .................. 48 
8.4. Treatment Overdose  ................................ ................................ .............................. 49 
8.5. Concomitant Medications  ................................ ................................ ..................... 49 
8.5.1.  Permitted therapy  ................................ ................................ ................................ ..49 
8.5.2.  Restricted Therapies  ................................ ................................ ............................. 49 
8.5.3.  Therapies for Treatment of IPF  ................................ ................................ ............ 50 
8.6. Fertility/Contraceptive Requirements  ................................ ................................ ...50 
8.6.1.  Acceptable Forms of Contraception  ................................ ................................ .....50 
9. RANDOMI ZATION PROCEDURE  ................................ ................................ ....52 
9.1. Blinding  ................................ ................................ ................................ ................ 52 
10. SAFETY ASSESSMENTS  ................................ ................................ .................. 53 
10.1.  Safety Monitoring Committee (SMC)  ................................ ................................ ..53 
10.2.  Adverse Events (AE)  ................................ ................................ ............................ 53 
10.3.  Recording Adverse Events  ................................ ................................ ................... 54 
10.4.  Assessment of Adverse Events  ................................ ................................ ............. 54 
10.4.1.  Serious Adverse Event (SAE)  ................................ ................................ .............. 54 
10.4.2.  Protocol -Defined Events of Special Interest  ................................ ......................... 55 
10.4.3.  Severity of Adverse Events  ................................ ................................ .................. 55 
10.4.4.  Relationship to Study Drug  ................................ ................................ .................. 55 
10.4.5.  Unexpected Adverse Reactions  ................................ ................................ ............ 56 
10.5.  Reporting Adverse Events  ................................ ................................ .................... 56 
10.5.1.  Diagnosis versus Signs and Symptoms  ................................ ................................ 56 
10.5.2.  Adverse Events Occurring Secondary to Other Events  ................................ ........ 56 
10.5.3.  Persistent or Recurrent Adverse Events  ................................ ............................... 57 
10.5.4.  Abnormal Laboratory Values  ................................ ................................ ............... 57 
10.6.  Discontinuation due to Adverse Events  ................................ ................................ 57 
10.7.  Reporting Serious Adverse Events and Adverse Events of Special Interes t ........ 57 
10.8.  Choosing Adverse Event Terms  ................................ ................................ ........... 58 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 8 
 
CONFIDENTIAL  
 10.9.  Pregnancy  ................................ ................................ ................................ ............. 58 
11. DATA ANALYSIS AND ST ATISTICAL PLANS  ................................ ............. 60 
11.1.  Sample Size  ................................ ................................ ................................ .......... 60 
11.2.  Popu lations for Analysis  ................................ ................................ ....................... 60 
11.2.1.  Primary Endpoint  ................................ ................................ ................................ ..60 
11.2.2.  Secondary endpoints  ................................ ................................ ............................. 60 
11.2.3.  Pharmacokinetics  ................................ ................................ ................................ ..61 
11.3.  Analyses  ................................ ................................ ................................ ................ 61 
11.3.1.  Safety Data  ................................ ................................ ................................ ............ 61 
11.3.2.  Efficacy Data  ................................ ................................ ................................ ........ 61 
11.3.3.  PK Data  ................................ ................................ ................................ ................. 61 
12. REGULATO RY, ETHICAL AND LEGA L OBLIGATIONS  ............................ 63 
12.1.  Ethical Consideration  ................................ ................................ ............................ 63 
12.2.  Institutional Review Board (IRB) and Regulatory Approval  ............................... 63 
12.3.  Insurance and Financial Disclosure  ................................ ................................ ......63 
12.4.  Essential Documentation Requirements  ................................ ............................... 63 
12.5.  Informed Consent  ................................ ................................ ................................ .63 
12.6.  Confidentiality  ................................ ................................ ................................ ......64 
12.7.  Trial Documentation and Data Storage  ................................ ................................ 64 
12.8.  Study Record Retention  ................................ ................................ ........................ 64 
12.9.  Disclosure of Information  ................................ ................................ ..................... 65 
12.9.1.  Publication  ................................ ................................ ................................ ............ 65 
13. ADMINSTRATIVE OBLIGA TIONS  ................................ ................................ ..66 
13.1.  Source Data  ................................ ................................ ................................ ........... 66 
13.2.  Data  Collection  ................................ ................................ ................................ .....66 
13.3.  Monitoring  ................................ ................................ ................................ ............ 66 
13.4.  Quality Control and Quality Assurance  ................................ ................................ 66 
14. REFERENCES  ................................ ................................ ................................ .....67 
15. APPENDICES  ................................ ................................ ................................ ......69 
Appendix  A SCHEDULE OF STUDY ASSESSMENTS  ................................ .................... 70 
Appendix  B Strong Inducers of cyp ISOenzymes  ................................ ................................ 73 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 9 
 
CONFIDENTIAL  
 LIST OF TABLES  
Table 1  CYP Substrates with Narrow Therapeutic Range  ................................ ................ 50 
Table  2 Grading for Adverse Events not Covered in the NCI -CTCAE  ............................ 55 
 
LIST OF APPENDICES  
Appendix  A SCHEDULE OF STUDY ASSESSMENTS  ................................ .................... 70 
Appendix  B Strong Inducers of CYP ISOenzymes  ................................ .............................. 73 
 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 10 
 
CONFIDENTIAL  
 LIST OF ABBRE VIATIONS  
AE Adverse event  
AESI  Adverse Event of Special Interest  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase  
AT Anaerobic threshold  
ATS  American Thoracic Society  
ATAQ  A Tool to Assess Quality of Life (ATAQ) in IPF  
AUC  Area under the  concentration time curve  
AUC (0-inf) Area under the concentration -time curve from zero extrapolated to infinity  
AUC (0-inf)/D Dose -normalized AUC (0-inf) 
AUC (0-last) Area under the concentration -time curve from time zero to the time of last 
quantifiable a nalyte concentration  
AUC (0-tau) Area under the concentration -time curve during a dosing interval  
AUC (0-tau)/D Dose -normalized AUC (0-tau) 
BP Blood Pressure  
BUN  Blood urea nitrogen  
CL Clearance  
Cmax Maximum concentration  
Cmax/D Dose -normalized C max 
Cmin Minimum concentration  
CNS  Central nervous system  
CPET  Cardiopulmonary Exercise Testing  
CRA  Clinical research associate  
CRF  Case Report Form  
CrCl  Creatinine c learance  
CRO  Contract research organization  
CV Coefficient of variation  
CYP  Cytochrome  
DL CO Diffusing Capacity of the Lung for Carbon Monoxide  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
FEV1  Forced expiratory volume in 1 second  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 11 
 
CONFIDENTIAL  
 FVC  Forced vital capacity  
GBT  Global Blood Therapeutics  
GCP  Good Clinical Practice  
GGT  Gamma glutamyl transferase  
Hb Hemoglobin  
HbA  Adult  hemoglobin  
HbS Hemoglobin S  
HbsAg Hepatitis B surface antigen  
β HCG  Human chorionic gonadotropin  
HCV  Hepatitis C virus  
hERG  Human Ether -à-go-go-Related Gene  
HIV Human immunodeficiency virus  
HV Healthy volunteers  
HR Heart rate  
HRR  Heart rate recovery  
HRRes  Heart rate reserve  
IB Investigator Brochure  
ICF Informed consent form  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IMP Investigational medicinal product  
INR International normalized ratio  
IPF Interstitial pulmonary fibrosis  
IRB Institutional Review Board  
IUD Intrauterine device  
IUS Intrauterine system  
LC-MS Liquid chromatography -tandem mass spectrometry  
MDRD eGFR  Modification of diet in renal disease estimate glomerular filtration rate  
MedDRA  Medical dictionary for regulatory activities  
6MWT  6-minute walk test  
NAC  N-acetylcysteine  
OEC  Oxygen equilibrium curve  
P20 Partial pressure of oxygen at which hemoglobin is 20% saturated  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 12 
 
CONFIDENTIAL  
 p50 Partial pressure of oxygen at which hemoglobin is 50% saturated  
PD Pharmacodynamic  
PDE  phosphodiesterase  
PK Pharmacokinetic  
PRO  Patient reported outcome  
PT Prothrombin time  
PTT Partial thromboplastin time  
ODC  Oxy-hemoglobin dissociation curve  
QTcF  Corrected QT interval using the Fridericia formula  
RBC  Red blood cell  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SaO2  Arterial oxygen saturation  
SCD  Sickle cell disease  
SD Standard deviation  
SGRQ  St George’s Respiratory Questionnaire  
SMC  Safety Monitoring Committee  
SpO 2 Peripheral capillary oxygen saturation  
t1/2 Apparent t erminal half life  
tmax Time of maximum concentration  
tmin Time of minimum concentration  
UCSD  SOBQ  University of California, San Diego Shortness of Breath Questionnaire  
ULN  Upper limit of normal  
VAS  Visual analog scale  
VE/VCO2 slope  Slope of relation between minute ventilation and CO2 production  
VO2 peak  Peak oxygen consumption  
VO2 peak/kg  Peak oxygen consumption/kg  
Vss Volume at steady state  
WBC  White blood cell  
z Apparent terminal rate constant  
 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 13 
 
CONFIDENTIAL  
 PROTOCOL SYNOPSIS  
Protocol Title  A Phase II  randomized, placebo -controlled study of GBT440 to evaluate 
the safety, tolerability, pharmacokinetics and effect on hypoxemia  in 
subjects with Idiopathic Pulmonary Fibrosis (IPF)  
Protocol Number  GBT440 -006 
Sponsor  Global Blood Therapeutics  
400 East Jamie Court Suite #101  
South San Francisco, CA  94080  
Study Drug  GBT440 capsules: 300 mg strength, administered orally .  
Matching placebo, administered orally . 
Objectives  Primary  
 To evaluate the safety and tolerability of multiple doses of GBT440 
administered to subjects with IPF .  
Secondary  
 To evaluate the effect of GBT440 on oxygen saturation at Days 15 
and 28 compared to baseline during 6 -minute walk testing 
(6MWT).  
 To evaluate the pharmacokinetic (PK) parameters of GBT440 in 
plasma and whole blood . 
Exploratory  
 To evaluate the effect of GB T440 on distance walked during the 
6MWT at Days 15 and 28 compared to baseline.  
 To evaluate the effect of GBT440 on IPF -related symptoms using 
patient reported outcomes (PROs) at Day 28 compared to baseline.  
 To evaluate the effect of GBT440 on cardiopulmon ary exercise 
testing  (CPET)  parameters at Day  29 compared to baseline.  
 To evaluate pulmonary function, including assessment of 
spirometry and Diffusing Capacity of the Lung for Carbon 
Monoxide  (DLco ) at Day 28 compared to baseline . 
 To evaluate the PK -pharmacodynamic ( PD) relationship of 
GBT440 at Days 15 and 28 compared to baseline.  
Study Design  This study is a randomized, placebo -controlled trial that will be conducted 
in two parts. Together, Parts A and B will provide safety and efficacy data 
across a range of GBT440 doses that are expected to improve oxygen 
saturation in the enrolled subjects.  
 In Part A , eligible IPF subjects will be randomized 1:1:1 to receive 
GBT440 900 mg (n  = 6) or 600 mg (n  = 6), or placebo (n = 6) 
administered orally as 300 mg capsules once daily for 28 days . The 
study site, subjects and Sponsor will be blinded to study treatment.  
 In Part B  eligible IPF subjects will be randomized 3:1:1 to receive 
GBT440 1500 mg (n  = 9) or 600 mg (n  = 3), or placebo (n = 3) 
administered orally as 300 mg capsules once daily for 28 days in 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 14 
 
CONFIDENTIAL  
 which the study site and subjects are blinded to study treatment. The 
Sponsor will be unblinded to study treatment.  
Subjects will participate in the study for approximately 79 days : screening 
(up to 21 days), treatment period (28 days) and follow -up period (30 days) 
with a total of 9 study site visits.  
The screening period for each subject commences when the subject 
undergoes the first study -specific screening assessment and must be 
completed  and evaluated before randomization (Day 1).   
Subjects may be rescreened up to two times, if deemed appropriate by the 
Principal investigator. The rescreening visit should not occur sooner than 
10 calendar d ays after the failed screening visit.  
Patients on a stable dose of pirfenidone or nintedanib and/or N -acetyl 
cysteine at screening are eligible for entry into the study . 
A Safety Monitoring Committee (SMC) is planned to review all safety 
data on an ongoing  basis throughout the study. If the SMC does not 
identify any clinically significant safety concerns in Part A, following 
review of data from approximately 18 subjects who have completed Day 
15, the Sponsor will initiate Part B of the study and randomise u p to an 
additional 15  subjects, to the three study treatment arms to better 
characterize the safety, tolerability and/or potential treatment response of 
GBT440 in subjects with IPF . 
The dose levels predicted to achieve the hemoglobin ( Hb) modification 
targets of ~20% to ~50% in IPF subjects are based on clinical PK and PD 
data from study GBT440 -001. Dose levels of 600 mg or 900  mg per day 
administered to healthy subjects for 15 days resulted in a mean Hb 
modifications of 24% and 38%, respe ctively. A dose level of 300 mg per 
day resulted in a mean Hb modification of 11%, which is below the PD 
effect that showed benefit in animal models of hypoxemia. A dose of 
1500  mg is expected to achieve a Hb modification target of ~50% .  
Part A Treatment:  
• GBT440 900 mg : 3 GBT440 300 mg capsules.  
• GBT440 600 mg : 2 GBT440 300 mg capsules and 1 placebo 
capsule.  
• Placebo : 3 placebo capsules.  
Part B Treatment:  
• GBT440 1500 mg : 5 GBT440 300 mg capsules  
• GBT440 600 mg:  2 GBT440 300 mg capsules and 3 placebo 
capsule s.  
• Placebo:  5 placebo capsules.  
In Part A two unblinded interim analyses of the primary and secondary 
endpoints are planned: i)  when approximately 9 subjects have completed 
their Day 28 study visit and ii) when approximately 18 subjects have 
completed their Day 15 study visit.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 15 
 
CONFIDENTIAL  
 Number of 
Subjects  In Part A, a total of approximately 18 subjects will be randomized 1:1:1 to 
either: 900 mg GBT440, 600 mg GBT440 or placebo .  
In Part B,  up to an additional 15 subjects will be randomized 3:1:1 to 
either: 1500 mg GBT440, 600 mg GBT440 or placebo .  
Replacement of 
Subjects  Subjects who do not complete at least 10 days of dosing for reasons 
unrelated to toxicity may be replaced . 
Number of Centers  The study will be conducted at approximately 10 –15 clinical sites  in the 
United States  
Duration of Study 
Participation  Approximately 79 days, including screening, treatment and follow -up 
periods  
Study Population  Inclusion Criteria  
1. Able and willing to provide signed informed consent to participate in 
this study.  
2. Documented diagnosis of IPF, as indicated in the 
ATS/ERS/JRS/ALAT 2011 guidelines.  
3. Adult males or females aged 45 -80 years inclusive at randomization  
4. Oxygen saturation (SpO 2) ≥ 88 % by pulse oximetry while breathing 
room air at rest  
5. Oxygen saturation (SpO 2) <88% and at least a 5% absolute decrease 
during the baseline 6 -minute walk test (6MWT) which is sustained for 
at least 10 seconds  
6. Able to walk at least 100 meters at completion of the baseline 6 MWT  
7. Weight ≥ 40 kg  
8. Subject is seronegative for recent hepat itis A (IgM anti -HAV), 
hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibody 
(anti-HCV), and human immunodeficiency virus antibody (anti -HIV) 
within 3 months of screening.  
9. Able, in the Investigator’s opinion, to complete the 6MWT unassisted 
at ba seline and Day 15 and Day 28 and comply with the study 
procedures, including attending all assessment visits and adhering to 
all study requirements and restrictions.  
10. Male or female of child bearing potential willing and able to use 
highly effective methods  of contraception from study start to 3 months 
after the last dose of study drug.  
Exclusion Criteria  
1. FEV1/FVC <70%.  
2. Requires supplemental oxygen therapy at rest.  
3. History of other interstitial lung diseases including but not limited to 
radiation, drug toxi city, sarcoidosis, hypersensitivity pneumonia, 
bronchiolitis obliterans, organizing pneumonia.  
4. History of clinically significant environmental exposure known to 
cause pulmonary fibrosis including but not limited to drugs (e.g. , 
methotrexate or amiodarone),  asbestos, beryllium, radiation and 
domestic birds.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 16 
 
CONFIDENTIAL  
 5. History of other medical conditions that are known or may result in 
interstitial lung disease. For example, any connective tissue disease 
including but not limited to scleroderma, 
polymyositis/dermatomyos itis, systemic lupus erythematosus and 
rheumatoid arthritis.  
6. AST, ALT or total Bilirubin >2 × ULN.  
7. Creatinine Clearance (CrCl) <30 mL/min/1.73 m2, calculated using 
the Modification of Diet in Renal Disease estimated Glomerular 
Filtration Rate (MDRD eGFR).  
8. Significant polycythemia defined as hemoglobin value >18 mg/dL.  
9. ECG with a QTcF >450 ms (males) or QTcF >470 ms (females). If 
ventricular pacing is noted on ECG, then QTcF intervals will not be 
calculated.  
10. Family or personal history of congenital long Q T syndrome.  
11. Female who is breast -feeding or pregnant.  
12. Known current malignancy or current evaluation for a potential 
malignancy or history of malignancy within the past 2 years prior to 
screening, except for appropriately treated non -melanoma skin 
carcinom a, carcinoma in situ of the cervix, or Stage 1 uterine cancer.  
13. Subject has used any of the following therapies within 30 days of 
screening:  
 Any cytotoxic, immunosuppressive or cytokine -modulating 
therapy including but not limited to: azathioprine, bosenta n, 
ambrisentan, cyclophosphamide, cyclosporine, etanercept, 
iloprost, infliximab, leukotriene antagonists, methotrexate, 
mycophenolate, tacrolimus  
 Imatinib mesylate, i nterferon gamma -1b, tyrosine kinase 
inhibitors (excluding nintedanib)  
14. Pulmonary hyperten sion requiring active therapy including but not 
limited to endothelin receptor inhibitors or PDE inhibitors (e.g., 
sildenafil, tadalafil).  
 Note: intermittent use of a PDE inhibitor for erectile dysfunction 
may be allowed after approval by the Medical Monitor.  
15. Hospitalization due to an exacerbation of IPF within 30 days of 
screening  
16. Subject plans to begin or has commenced pulmonary rehabilitation 
within 30 days of screening  
 Subjects on a stable exercise regimen at screening or whose 
regimen, in the opin ion of the investigator, is not expected to 
change at any time during the entire study will be considered 
eligible for the study  
17. Corticosteroids ( >10 mg per day of prednisone or an equivalent) 
within 30 days of screening.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 17 
 
CONFIDENTIAL  
 18. Current smoker (including use of e Cigarettes or vaporizing) or history 
of smoking within 3 months from screening . 
19. Clinical evidence of active infection, including but not limited to 
bronchitis, pneumonia, sinusitis, urinary tract infection or cellulitis, 
within 14 days of screening  
20. Active tuberculosis requiring treatment within the last 12 months  
 Testing for latent tuberculosis is not required  
21. Currently or, in the opinion of the investigator, soon to be listed for 
lung transplant.  
22. History of unstable or deteriorating cardiac or pulmonary d isease 
(other than IPF) within 6 months of screening including but not 
limited to the following:  
 Unstable angina pectoris or myocardial infarction or elective 
coronary intervention  
 Congestive heart failure requiring hospitalization  
 Uncontrolled clinically significant arrhythmias  
23. Any condition possibly affecting drug absorption, such as previous 
surgery on the stomach or small intestine . 
24. Participated in another clinical trial of an investigational drug (or 
medical device) within 30  days or 5 -half-lives, whic hever is longer, 
prior to screening, or is currently participating in another trial of an 
investigational drug (or medical device).  
25. Known hypersensitivity to any component of the study drug.  
26. Subject who, for any reason, is deemed by the investigator to be 
inappropriate for this study; or has any condition (such as addictive or 
psychosocial issues) which would confound or interfere with the 
evaluation of the safety, tolerability, or PK of the investigational drug; 
or is unable to comply with the study protoc ol. 
27. History of mental illness within the last 5 years, unless the subject 
fulfills one of the following conditions:  
 The subject has not required or been prescribed any psychiatric 
medication (including but not limited to antidepressants or 
anxiolytics) wit hin 12 months before screening and, in the 
opinion of the investigator, the subject is able and safe to 
participate in the study  
 The subject has been on a fixed regimen of psychiatric 
medications for at least 6 months before screening and displays 
no sign of acute mental illness and, in the opinion of the 
investigator, the subject is able and safe to participate in the study  
Study Evaluations  Safety Assessments  
Subject safety and tolerability will be monitored throughout the study 
using standard measures,  including physical examinations, vital signs 
(including blood pressure, pulse rate, body temperature, respiratory rate), 
12-lead ECGs (collected in triplicate), safety labs, urinalysis, concomitant 
medication usage and adverse event monitoring.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 18 
 
CONFIDENTIAL  
 Safety laboratory assessments include: hematology, serum chemistry, 
urinalysis, coagulation panel, Hepatitis A, B, C and HIV serologies and 
pregnancy tests.  
Clinical Assessments  
Spirometry and Diffusing Capacity of the Lung for Carbon Monoxide 
(DLco) Measurements  
All equipment, procedures, and personnel qualifications for the assessment 
of lung function are based on the recommendations of the American 
Thoracic Society ( ATS 2005 ) and will be performed at each site using 
local equipment. Spirometry measurements will include FVC, FEV 1 and 
flow-volume loops. Pre and post -bronchodilator assessments will not be 
performed. DL CO will be measured at each site by determining the 
diffusing/transfer capacity of the lung for carbon monoxide  
Oxygen Sa turation  
During screening and with all scheduled vital sign assessments resting, 
room air oxygen saturation (SpO 2) will be measured by pulse oximetry 
(provided by the Sponsor) whilst the subject is seated and resting for at 
least 5  minutes. Before recordin g the SpO 2 value in the eCRF the study 
staff should ensure the measurement is stable, which may require 
continuous or repeated measurements and ensuring the subject is resting.  
SpO 2 will be also be collected as part of the 6MWT and during cardio -
pulmonary  exercise testing.  
6-Minute Walk Test (6MWT) and Borg Scale of Perceived Exertion  
Functional exercise capacity will be evaluated at baseline, Days 15, 28 and 
58 using the 6 -minute walk test.  The 6MWT will be performed without 
the subject using supplementar y oxygen. Oxygen may be used at any time 
during the 6MWT, if in the opinion of the Investigator or testing 
technician it is required for safety reasons. The 6MWT should then be 
stopped.  
Guidelines developed by the ERS/ATS will be used for conducting the te st 
and interpreting the results ( ATS 2002  and Holland 2014 ).  
As part of the 6MWT SpO 2, heart rate and the Borg dyspnea scale will be 
measured  prior to starting the test, during the test, at completion of the 
test, 1  minute and 2 minutes after test completion.  
Cardiopulmonary Exercise Testing (CPET)  
Symptom -limited cardiopulmonary exercise testing using a bicycle 
ergometer will be performed  at baseline and Day 29. At baseline and 
during the exercise period the collected data will include but is not limited 
to: SpO 2 and arterial blood gases, VO 2 max, ventilation and lactate 
thresholds. Guidelines developed by ATS and American College of Chest  
Physicians will be used for conducting the test and interpreting the results 
(ATS 2003 ). 
St George’s Respiratory Questionnaire (SGRQ)  
The SGRQ is a symptom -specific 2 -part, subject self -administered 
questionnaire that assesses shortness of breath while do ing a variety of 
activities of daily living. This questionnaire comprises three domains: 
symptoms, activity and impact. Paper questionnaires will be provided to 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 19 
 
CONFIDENTIAL  
 sites prior to subject enrollment  
University of California, San Diego Shortness of Breath Quest ionnaire 
(UCSD)  
The UCSD is a 24-item assessment of breathlessness associated with 
various activities of daily living. The response for each item is measured 
on a 5 -point Likert scale from 0 (none at all) to 5 (maximal or unable to 
perform). Refer to the  Procedure Manual for a copy of the questionnaire. 
Paper questionnaires will be provided to sites prior to subject enrollment . 
Borg Dyspnea Scale  
The Borg Dyspnea scale is a one -item assessment, self -administered by 
the patient administered as part of the 6 MWT.  The instrument will be 
used to assess dyspnea from the patient’s perspective. The Scale ranges 
from 0 (Nothing at all) to 10 (Absolute maximum/Highest possible). See 
Procedure Manual for a copy of the assessment. A paper scale will be 
supplied to si tes prior to subject enrollment.  
A Tool to Assess Quality of Life (ATAQ) in IPF  
ATAQ questionnaires (IPF Symptoms Questionnaire and IPF Impacts 
Questionnaire) will be administered in Part B of this study.  
End of Study Questionnaire  
The end of study questio nnaire is an 8-item survey to evaluate the subjects' 
experience while on the study including symptoms, changes in oxygen 
saturation and use. This is a self -administered survey to be completed 
during the Day 58 visit. The survey is to be completed by subjec ts enrolled 
under Part B of the trial.  
Visual Analog Scale (VAS) for Cough Severity  
Cough will be assessed using a VAS in which the subject will indicate the 
severity of their cough by drawing a mark on a 100 mm scale, which 
ranges  from 0 - “no cough” to 100  mm - “worst cough severity”. A paper 
scale will be supplied to sites prior to subject enrollment.   
Pharmacokinetic Assessments  
Plasma and whole blood concentrations of GBT440 will be measured. PK 
samples will be collected at the  following times: on Days 1 and 28 : 
pre-dose, and 2 hours post dose (+/- 15 minutes); Day 2 : 24 hours (+/- 2 
hours) after the Day 1 dose and prior to receiving the Day 2 dose; Days 8 
and 15: pre-dose only; during follow -up on Days 45 and 58.  
Restricted 
Concomitant 
Therapy  Subjects should not take the following medications within 14 days prior to 
Screening and during the entire study:  
 Strong inducers of CYP3A4/CYP3A5, CYP2B6, CYP2C9 and 
CYP2C19 (these medications  may decrease the blood concentration 
of GBT440 )  
 Herbal medications (e.g., St. John’s Wort)  
The following medications should be used with caution:  
 CYP3A4 substrates with a narrow therapeutic index ( e.g., 
alfentanil, dihdroergotamine, ergotamine, fentanyl, pimozide, 
quindine ; GBT440  may increase the plasma concentration of these 
medications ) 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 20 
 
CONFIDENTIAL  
 Note:  based on results from the drug -drug interaction studies, 
co-administration of GBT440 with pirfenidone or nintedanib is considered 
to be acceptab le. 
Statistical Methods  Sample Size  
The sample size in this study was not selected based on statistical 
considerations but to determine preliminary safety, tolerability, PK, 
laboratory and clinical effects of GBT440 in IPF subjects.   
Study Endpoints  
Primary Endpoint  
 Treatment -emergent advers e events and tolerability.  
Secondary Endpoints  
 Change  and percentage change from baseline in resting SpO2 at Days 
15 and 28 measured prior to beginning the 6MWT .  
 Change and percentage change from baseline in end -of-6MWT SpO2 
at Days 15 and 28.  
 Change and percentage change from baseline in lowest SpO2 value 
measured during  the 6MWT at Days 15 and 28 . 
 Pharmacokinetic (PK) parameters of GBT440 in plasma and whole 
blood, including but not limited to maximum concentration (C max), 
minimum concentratio n (C min) at steady state in GBT440 treated 
subjects . 
Exploratory  Endpoints  
 Change and percentage change from baseline in distance walked 
during the 6MWT at Days 15 and 28.  
 Time to first SpO2 < 88% that is sustained for at least 10 seconds 
during the 6MWT at  Days  15 and 28.  
 Area under the SpO 2 curve (AUC) during the 6MWT measured at 
baseline, Day 15 and Day 28.  
 Change from baseline in PRO scores using SGRQ, UCSD, ATAQ  
(only subjects enrolled in Part B) and the Borg Scale of Perceived 
Exertion questionnaires and cough VAS at Days 15 and 28 . 
 Change and percentage change from baseline in cardiopulmonary 
exercise testing parameters at Day 29.  
 Change and percentage change from baseline in lung function, 
including FVC and DL CO at Day 28. 
 PK/PD relationship in subjects receiving GBT440 from Baseline to 
Day 15 and Day 28. 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 21 
 
CONFIDENTIAL  
 1. INTRODUCTION  
1.1. Disease Background  
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown etiology  that is 
characterized by progressive fibrotic destruction of the lung, resulting in worsening dyspnea 
and progressive loss of lung function [Raghu 2011 ]. IPF is the most common type of 
interstitial lung disease with a  high mortality rate [Michaelson 2000 ]. While the course of the 
disease is variable, the prognosis is uniformly poor, with  a median survival of about 
3-5 years after diagnosis. [Raghu 2006 , King 2001 , Nicholson 2000 ]. In the United States, it 
is estimated to affect up to 200,000 people with approximately 50,000 new cases dia gnosed 
each year [Raghu 2006 ] and approximately 40,000 dying  each year [Olson 2012 ]. IPF is 
typically seen in older adults, more commonly in men than women, usually occurring 
between the ages of 50 -80 years, with a median age of 65 at diagnosis [Raghu 2006 ]. The 
natural course of IPF is variable. As the interstitial fibrosis and architectural distortion 
advance, the lung becomes increasingly non -compliant, and the work of breathing and 
dyspnea increase. The lungs lose their ability to transfer oxygen into the bloodstream 
resulting in hypoxemia, tissue hypoxia, and ultimately organ dysfunction and symptoms. 
Subject s with IPF typically experience slowly progressive worsening of lung function over 
time, with the development of significant co -morbidities, the use of supplemental oxygen and 
frequent hospitalizations in the late stage of the disease [Raghu 2011 ]. Supplemental oxygen 
relieves dyspnea, prevent s secondary pulmonary hypertension and improves functional 
status, but requires equipment for oxygen administration which can limit patient  mobility and 
quality of life.  
There are two marketed products available for the treatment of IPF, nintedanib and 
pirfenidone which were ad ded to the American Thoracic Society treatment recommendations 
in 2015 [ Raghu  2015 ]. In clinical studies, these products demonstrated an effect on forced 
vital capacity and decline in lung function, but did not show an effect o n survival or disease 
modification . Furthermore , these therapies do not improve hypoxemia nor did they clearly or 
consistently improve disease symptoms such as dyspnea [ Richeldi 2014 , King 2014 ]. IPF 
remains a disease with high unmet medical need requiring novel therapies that address not 
only the underlying fibrosis but also secondary co -morbidities and that provide improvement 
in the patients’ quality of life . 
1.2. GBT440  
Global Blood Therapeutics (GB T) has developed GBT440, a novel small molecule allosteric 
modulator of hemoglobin (Hb) oxygen affinity , that is currently being investigated for the 
treatment of sickle cell disease (SCD) . GBT440 binds to the Hb α chain, and thus has the 
same pharmacodyna mics effect on normal adult h emoglobin (HbA) than on sickle  
hemoglobin (HbS). In SCD, GBT440’s effect on HbS was expected to decrease red blood 
cell sickling, which was confirmed in preliminary Phase I/II data [ Lehrer -Graiwer 2015 ]. 
Likewise for IPF , GBT440’s effect on HbA is expected to increase oxygen uptake in the  
lungs , improve hypoxemia  and oxygen delivery to tissues and in turn provide significant 
benefit  to IPF patients . 
In IPF , hypoxemia results from  ventilation -perfusion mismatch and ineffici ent gas exchange 
at the alveolar -capillary barrier. The resultant reduced oxygen saturation (SpO 2) leads to 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 22 
 
CONFIDENTIAL  
 insufficient  oxygen delivery to tissues and tissue hypoxia, and in turn numerous adverse 
systemic effects including exercise intolerance with associ ated desaturation and pulmonary 
hypertension. As demonstrated by the use of supplemental oxygen therapy, i mproving 
oxygenation  clearly provides clinical benefit ; with improvement in  dyspnea, functional 
capacity, quality of life, and prevention of disease associated complications . [Eaton. 2004 ] 
Based on it’s mechanism of action, GBT440 is expected to increase Hb -O2 saturation at low 
alveolar oxygen tensions and provide similar benefit to patients with IPF.  In support o f this 
hypothesis, individuals with naturally occurring high affinity Hb mutations are 
physiologically adapted to the low oxygen tensions present at high altitude and are able to 
load and deliver more oxygen than normal controls [Hebbel 197 8]. Furthermore, numerous 
animal models have shown that increasing Hb oxygen affinity during acute and chronic 
hypoxia improves arterial oxygenation, cardiovascular function and survival. [Eaton  1974 , 
Yalcin and Cabrales 2012 ] Based on these observations and its ability to safely increase Hb 
oxygen affinity in  humans (both healthy subjects  and patients with SCD in the ongoing 
GBT440 -001 study), GBT440 may improve arterial oxygenation, tissue oxygen delivery, 
symptoms and functional status in subjects with IPF.  
1.3. Rationale for Study  
GBT440, a hemoglobin modifier that causes a left -shift in th e oxy-hemoglobin dissociation 
curve (ODC ) has the potential to enable increased oxygen uptake in the lungs  and O2 
saturation, resulting in improved oxygen delivery to tissues. A key therapeutic  goal for IPF 
patients  with GBT440 is to reduce hypoxemia and i mprove the associated debilitating 
symptoms and functional impairment. Supplemental oxygen therapy is a well -established 
treatment in IPF and other chronic hypoxemic pulmonary diseases where it improves 
symptoms, functional status and (in the case of C hronic Obstructive Pulmonary Disease ) 
improves survival. Supplemental oxygen therapy has disadvantages, however, which can 
negatively impact patient quality of life including the burden and decrease d mobility from 
the required oxygen delivery devices, local complications , poor compliance and  inadequate 
symptomatic relief . GBT440 therapy may be able to provide many of the same clinical 
benefits of oxygen therapy without the negative aspects of oxygen supplementation. GBT440 
could also be useful as an adjunct to oxygen therapy in more severe subject s who are not 
adequately oxygenated despite noninvasive oxygen therapy or to allow the use of lower flow, 
more convenient oxygen equipment for the same clinical benefit. This study will gather 
preliminary data , across a  range of GBT440 doses , to determine whether  GBT440 could 
improve : oxygen saturation  at rest and with exercise , IPF-related symptoms  and exercise 
capacity.  
GBT440 has been administered to healthy subjects  and subjects with SCD. Overall, multiple 
doses of G BT440 have  been well tolerated across a broad range of doses (300 mg –1000mg ) 
for up to 90 days.  Results from this study  will inform future development of GBT440 in IPF 
subject s. 
1.4. Nonclinical Data  
An overview of the key nonclinical data is provided below.  For a more detailed discussion of 
the nonclinical pharmacology, pharmacokinetic (PK) and toxicology studies conducted to 
date, please refer to the GBT440 Investigator’s Brochure (IB) . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 23 
 
CONFIDENTIAL  
 1.4.1.  Nonclinical Pharmacology  
In vitro pharmacology studies were conducted to  characterize the pharmacodynamic (PD) 
effects of GBT440. These studies demonstrated that GBT440 binds to Hb, modulates Hb -O2 
affinity and maintains the oxyHb state during deoxygenation. In addition, these studies 
showed that GBT440 -modified Hb retains the  Bohr Effect, which is the ability to augment 
oxygen delivery in metabolically active (low pH) tissues. This should preserve the ability of 
GBT440 -modified  hemoglobin to off -load oxygen to metabolically active tissues, despite its 
increased affinity for ox ygen.  
In vivo pharmacology studies were performed in murine models of acute hypoxia challenge 
and pulmonary hypoxemia (lipopolysaccharide [LPS] -induced acute lung injury [ALI] and 
bleomycin induced lung fibrosis and hypoxemia. These in vivo studies demonst rated that 
pharmacologically increasing Hb -O2 affinity in these mouse models of pulmonary 
hypoxemia resulted in improved O 2 saturation, translating into improved physiologic 
endpoints and survival.  
1.4.2.  Safety Pharmacology  
Safety assessments of GBT440 in three in vivo studies did not identify any biologically 
significant effects in the central nervous system ( CNS ) and respiratory system. There were 
minor effects in the cardiovascular ( CV) safety pharmacology studies, with a mild increase in 
systolic BP at higher  doses (1000  mg/kg) and a small decrease (15.3%) in hERG channel 
current at 10µM. Based on these results, there appears to be a low risk to humans for adverse 
effects on CNS, respiratory, or CV function.  
1.4.3.  Pharmacokinetics  
Pharmacokinetic (PK) evaluation sho wed that GBT440 had low blood clearance (CL), low 
blood V ss, and long  terminal t½ and was well absorbed in all animal species tested.  GBT440 
whole blood concentrations were much higher than plasma concentrations (calculated RBC : 
plasma  ratio ~150:1), consistent with a high affinity and specificity of GBT440 for Hb. The 
PK properties of GBT440 in animals suggest that it will preferentially bind to Hb and be 
slowly but completely eliminated from the body.  With increasing doses in rats and  dogs, the 
exposure with GBT440  is less than dose -proportional .  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 24 
 
CONFIDENTIAL  
 1.4.4.  Metabolism  and Potential Drug Interactions  
Metabolism was the major route of elimination of GBT440 in humans.  Renal excretion was a 
minor elimination pathway . In vitro metabolism studies indicate that GBT440 could be 
metabolized by several CYP enzymes, i.e., CYP1A1, 1B1, 2B6, 2C9, 2C19, 3A4, and 3A5.  
However, in total, the data show that the exposure of GBT440 is unlikely to dramatically 
increase ( <1.7-fold) whe n coadministered  with a CYP inhibitor.  Refer to  Section 8.5.2  for 
restricted therapies in this study.  
GBT440 has also been evaluated as a potential inhibitor /substrate  of various membrane 
transporters. Refer to the GBT440 IB for further details of these  studies . 
1.4.5.  Toxicology  
The toxicity of GBT440 has been evaluated in single dose , repeat dose  and reproductive  
toxicity studies . The genotoxic potential of GBT440 has been evaluated in a battery of in 
vitro and in vivo assays . The details of the nonclinical t oxicology pr ogram, including 
toxicokinetics, are provided  in the GBT440 IB. 
1.5. Clinical Development of GBT440  
Clinical studies to date have been conducted primarily in healthy subjects and subjects with 
SCD.  They include an ongoing Phase I/II study (GBT440 -001), Phase II adolescent SCD 
study (GBT440 -007) and 8 (4 complete and 4 ongoing) Phase  I clinical pharmacology 
studies in healthy subjects.  GBT440 is also being evaluated in an ongoing Phase II study in 
IPF subjects using oxygen at rest (GBT440 -026). 
The Ph ase I/II study (GBT440 -001) is a randomized, placebo -controlled, ascending dose 
study evaluating the safety, tolerability, PK, and PD effects of single and multiple doses of 
orally administered GBT440 in healthy subjects and subjects with SCD.  Healthy subj ects 
have received multiple -doses of 300 mg to 900 mg/day of GBT440 for up to 15  days.  SCD 
subjects have received multiple doses of 500  mg to 1000 mg/day for up to 28  days, and 
700 mg or 900 mg/day for up to 90  days; some subjects (900 mg) are continuing t reatment 
for up to 6 months under a separate protocol (GBT440 -024).  
The Phase II study in adolescent subjects with SCD (GBT440 -007) is an open -label, single  
dose and multiple  dose PK study of GBT440 in pediatric subjects, ages 12 to 17 years.   
The eight clinical pharmacology studies (GBT440 -002, GBT440 -003, GBT440 -004, 
GBT440 -005, GBT440 -008, GBT440 -017, GBT440 -018 and GBT440 -019) are evaluating  
the absorption, metabolism, excretion,  food effect,  relative bioavailability  and drug -
drug- interactions (DDI)  of GBT440.  
The Phase II IPF study (GBT440 -026) is an open label  trial evaluating the safety of GBT440 
and its effects on oxygen saturation and supplemental oxygen requirements in IPF subjects  
who use oxygen at rest . GBT440 is being  dosed at  900 mg orally d aily for 90 days.  
Please r efer to  the GBT440 IB for additional  details  regarding GBT440 development  and all 
clinical studies . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 25 
 
CONFIDENTIAL  
 1.5.1.  Safety Findings  in Study GBT440 -001 
To date, GBT440 has been well tolerated over a range of doses administered to healthy and 
SCD subjects, for up to 90 days.   
As of 30 September 2016,  a total of 259 subjects have received at least 1 dose of GBT440:  
205 healthy subjects , 47 adult SCD subjects  and 7 pediatric SCD subjects .  
The majority of the adverse events ( AEs) were mild or  moderate (Grade 1 or Grade 2), most 
commonly headache or diarrhea, and no clinically significant findings in vital signs, 12 -lead 
electrocardiograms (ECGs) , or laboratory safety values  were identified . 
In the SCD subjects dosed for 90 days, the majority of th e AEs were also mild or moderate 
(Grade 1 or Grade 2).  The most common AEs, occurring in ≥ 2 subjects and at a similar 
frequency in GBT440 and placebo -treated subjects, were headache, back pain, fatigue, and 
rhinitis.  
The AEs that occurred at a higher rate  in subjects receiving GBT440 included cough, 
diarrhea , and rash, of which diarrhea and rash were considered treatment -related by the 
Investigator . No episodes of anaphylaxis, anaphylactoid, or hypersensitivity reactions were 
reported.  
Rashes were morbilliform in nature, typically involved the trunk or extremities, associated 
with mild pruritus, resolving within 2 to 5 days (in one case with continued dosing), and were 
not associated with any systemic features.  
Overall, 10 serious adverse events ( SAEs) have been reported  as of 30 September  2016 , in 
10 subjects with SCD, considered by the Investigator to be not related to the study drug.  
There were 7 events of sickle cell crisis (Grade 3), all occurring off treatment during 
follow -up (1  placebo; 6 GB T440); one event of presumed infection with hemolysis (Grade 2) 
(GBT440); one event of an ovarian cyst (Grade 3), occurring after the last dose of study drug 
(GBT440) and one event of Grade 2 upper respiratory tract infection requiring hospitalization 
(GBT 440). 
Please refer to the GBT440 IB for additional details on  GBT440 safety findings .  
1.5.2.  Pharmacokinetic Parameters  
The mean PK results of GBT440 from analy zed samples to date , derived from whole blood 
concentration -time profiles , shows that both C max and AUC increased proportionally with 
study drug dose for both single or multiple doses. The exposure of GBT440 at steady -state 
was consistent with accumulation predicted based on the single dose data.  
For the same dose, GBT440 exposure was lower and the  T1/2 was significantly shorter in 
subjects with SCD compared with healthy subjects. At steady -state, the exposure in subjects 
with SCD was also lower than that observed in healthy subjects. Since IPF patients will most 
likely have hematocrit values within  the normal range, PK of GBT440 in these patients are 
expected  to be similar to that of healthy volunteers.  Please refer to the GBT440 IB for 
additional details of GBT440 PK parameters . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 26 
 
CONFIDENTIAL  
 1.5.3.  Dose Rationale  
The selection of GBT440 doses for investigation in IPF patie nts is based on 
pharmacodynamic  (PD) targets that are expected to correspond  to an increase in Hb -O2 
affinity which may  result in a clinically significant increase in oxygenation. These PD targets 
are derived  from data from three nonclinical pharmacology studies that included a hypoxia 
challenge model and two models of pulmonary hypoxemia (refer to the IB for details of these 
studies). Based on the in vivo data the lower limit for treatment response during exe rcise -
induced desaturation is expected to be ~20% Hb occupancy by GBT440 .  
The dose levels predicted to achieve the Hb modification targets of ~20% to ~50 % in IPF 
subjects are based on clinical PK and PD data from study GBT440 -001. Dose levels of 
600 mg or 900 mg per day administered to healthy subjects for 15 days resulted in a mean Hb 
modifications of 24% and 38%, respectively. A dose level of 300 mg per day resulted in a 
mean Hb modification of 11%, which is below the PD effect that showed benefit in ani mal 
models of hypoxemia.   
The safety of the proposed  doses of 600 mg and 900 mg  in the in itial c ohort (Part A) of 
approximately 18 subjects and the safety of pursuing parallel dosing in this study are based 
on the totality of available nonclinical and clin ical safety data.  The expansion Cohort (Part B) 
of 15 subjects will have 3 dose arms: 1500  mg, 600  mg and placebo.  Addition of a higher 
dose is supported by : the acceptable safety profile collected from the Part A  subjects dosed to  
date in this study ; review by the Safety Monitoring Committee of safety data from 
12 subjects who completed up to 28 days and 16 subjects who completed 15 days of dosing  
in Part A  and Safety Monitoring Committee agreement to proceed with the evaluation of 
GBT440 1500 mg; cont inued favorable safety profile in ongoing studies evaluating GBT440 
in subjects with SCD, including continued dosing for up to 6 months ; and an anticipated 
dose-dependent improvement in oxygen saturation . Guidelines for the safety review of Part 
A and Part  B of the trial are outlined in the Safety Monitoring Committee section ( Section 
10.1). 
1.5.4.  Potential Risk of GBT440 Treatment  
1.5.4.1.  Tissue Hypoxia  
There is a theoretical r isk of tissue hypoxia in subjects treated with GBT440 based on the 
mechanism of action  and potential associated impairment in O 2 offloading at the tissues . 
However, i n vitro data show that GBT440  modified Hb - remains sensitive to the Bohr effect  
and in vivo data from animal models of pulmonary hypoxemia are consistent with increased 
oxygen extraction and consumption by tissues.  Furthermore , clinical data from subjects 
receiving study drug and those participating in maximal cardio -pulmonary exerci se tests in 
the ongoing Phase I/II study, GBT440 -001, have not identified a concern with tissue hypoxia.  
Please r efer to the GBT440 IB  for further det ails. 
IPF subjects in this study will be closely monitored for subclinical evidence of worsening 
tissue hy poxia as measured by erythrocytosis, increased resting heart rate and erythropoietin 
and laboratory tests indicating organ injury (e.g. liver aminotransferases ). To date, none of 
these findings have been documented in Part A subjects dosed in this study.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 27 
 
CONFIDENTIAL  
 1.5.5.  Conclusions  Based on Clinical Study  Data  
The emerging experience from clinical studies in healthy volunteer s, SCD and approximately  
16 IPF subjects from Part A of this study (reviewed by the SMC) , having received  GBT440 
across a wide range of doses , has shown that GBT440 is well tolerated and no clinically 
significant sa fety signal has been identified. Based on these results  it is anticipated that 
GBT440 will have favorable benefit -to-risk profile in  IPF subjects , enrolled in both Parts A 
and B of th is study . 
The steady -state exposure and PD effect, which are predicted for the  600 mg  and 90 0 mg  
dose levels in Part A , have been demonstrated to be safe and tolerated in the healthy subjects 
treated with GBT440 for 15 days in the Phase I/II study (GBT440 -001). The 1500 mg  dose to 
be included in Part B is supported by the safety profile of the subjects  in the  600 mg  and 90 0 
mg dose arms  in this study  and an anticipated dose -dependent improvement in oxygen 
saturation . Furthermore, safety experi ence in SCD subjects treated for 90 days supports the 
proposed 28  day treatment duration in IPF subjects.  
 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 28 
 
CONFIDENTIAL  
 2. STUDY OBJECTIVES  
2.1. Primary Objective  
To evaluate the safety and tolerability of multiple doses of GBT440 administered to subjects 
with IPF  
2.2. Secondary O bjectives  
• To evaluate the effect of GBT440 on oxygen saturation at Days 15 and 28 compared to 
baseline during the 6-minute walk testing (6MWT ). 
• To evaluate the pharmacokinetic (PK) parameters of GBT440 in plasma and whole 
blood . 
2.3. Exploratory Objectives  
 To evaluate the effect of GBT440 on distance walked during the 6MWT at Days 15 and 
28 compared to baseline . 
 To evaluate the effect of GBT440 on IPF -related symptoms using patient reported 
outcomes (PROs) at Day 28 compared to baseline . 
 To evaluate the effect of GBT440 on cardiopulmonary exerc ise testing parameters at 
Day 29 compared to baseline . 
 To evaluate pulmonary function, including assessment of spirometry and Diffusing 
Capacity of the Lung for Carbon Monoxide  (DLco ) at Day  28 compared to baseline . 
 To eva luate the PK -PD relationship of GBT440 at Days 15 and 28 compared to baseline . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 29 
 
CONFIDENTIAL  
 3. INVESTIGATIONAL PLAN  
3.1. Study Design  
This study is a randomized, placebo -controlled trial that will be conducted in two parts. 
Together , Parts A and B will provide safety and efficacy data across a range of GBT440 
doses that are expected to improve oxygen saturation in the enrolled subjects.  
 In Part A  (Figure  1) eligible IPF subjects will be randomized 1:1:1 to receive GBT440 
900 mg (n  = 6) or 600 mg (n  = 6), or placebo (n  = 6) administered orally as 300 mg 
capsules once daily for 28 days . The study site, subjects and Sponsor will be blinded to 
study treatment.  
 In Part B  (Figure  2) eligible IPF subjects will be randomized 3:1:1 to receive GBT440 
1500 mg (n  = 9) or 600 mg (n  = 3), or placebo (n = 3) administered orally as 300 mg 
capsules once daily for 28 days in which the study site and subjects are blinded to study 
treatment. The Sponsor will be unblinded to study treatment.  
A signed and dated informed consent form (ICF) must  be obtained  before any screening 
procedures or study -specific tests may be performed.   
The screening period for each subject commences when the subject undergoes the first 
study -specific screening assessment and must be completed  and tests evaluated before 
randomizat ion (Day 1).  Subjects may be rescreened up to two times, if deemed appropriate 
by the Principal investigator.  The rescreening visit should not occur sooner than 10 calendar 
days after the failed screening visit . 
Patients on a stable dose of pirfenidone or nintedanib and/or N -acetyl cysteine are eligible for 
entry into the study . 
After the Screening visit the study includes the following study periods :  
• Treatment period (28  days) : subjects  will be randomized (1:1:1) to one of three treatment 
groups  in Part A  (Figure  1) and randomized (3:1:1) to one of three treatment groups in 
Part B ( Figure  2); subjects will receive :  
Part A:  
- Group 1: GBT440 900 mg ; three  300 mg GBT440 capsules,  daily orally .  
- Group 2: GBT440 600 mg ; two 300 mg GBT440 capsules and one placebo capsule , 
daily orally . 
- Group 3: Placebo : three placebo capsules , daily orally . 
Part B:  
- Group 1: GBT440 1500 mg ; five, 300 mg GBT440 capsules,  daily orally .  
- Group 2: GBT440 60 0 mg ; two 300 mg GBT440 capsules and three  placebo capsule , 
daily orally . 
- Group 3: Placebo: five placebo capsules , daily orally . 
• Safety follow up ( 30 days) : safety will be assessed for at least 5 half -lives after the last 
dose of GBT440.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 30 
 
CONFIDENTIAL  
 Figure  1 Study Design  – Part A  
 
Figure  2 Study Design  – Part B  
 
Subjects who do not complete at least 10 days of dosing  for reasons unr elated to toxicity may 
be replaced.  
In Part A , two unblinded interim analyses of the primary and secondary endpoints are 
planned: i)  when approximately 9 subjects have completed their Day 28 study visit and ii) 
when approximately 18 subjects have completed  their Day 15 study visit .  
A Safet y Monitoring Committee (SMC) is planned to review all safety data on an ongoing 
basis throughout the study ( refer to  Section 10.1). If the SMC does not identify any clinically 
significant safety concerns in Part A , following review of data from approximately 18 
subjects who have completed Day 15 , the Sponsor will initiate Part B of the study and  
randomise  up to an additional 15 subjects, to the three study treatment arms to better 

Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 31 
 
CONFIDENTIAL  
 characterize the  safety, tolerability and/or potential treatment response of GBT440 in subjects 
with IPF.  
In the eventuality that one treatment arm is discontinued , subjects may be randomised 1:1 to 
the remaining study drug treatment group or placebo. Therefore, the tria l size is 
approximately 33 subjects . 
The end of the study is defined as the date  when the last patient last visit occurs, which is 
expected to be approximately 58 days after the last patient is randomised.  
This study will be performed in compliance with th e protocol, ICH Good Clinical Practice 
(GCP) and applicable regulatory requirements.  Aspects of the study concerned  with the 
Investigational Medicinal Product (IMP)  will meet the requirements of Good Manufacturing 
Practice.  
  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 32 
 
CONFIDENTIAL  
 3.2. Endpoints  
3.2.1.  Primary Endpoint  
The primary endpoint is treatment -emergent adverse events and tolerability.  
3.2.2.  Secondary  Endpoint s 
• Change  and percentage change from baseline in resting SpO 2 at Days 15 and 28 
measured prior to beginning the 6MWT .  
• Change  and percentage change from baseline in end-of-6MWT SpO 2 at Days 15 and 28 .  
• Change and percentage change from baseline in l owest  SpO 2 value measured during  the 
6MWT at Da ys 15 and 28.   
• Pharmacokinetic (PK) parameters of GBT440 in plasma and whole blood, including but 
not limited to maximum concentration (C max), minimum concentration (C min) at steady 
state in GBT440 treated subjects . 
3.2.3.  Exploratory Endpoints  
• Change and percentage change from baseline in distance walked during the 6MWT at 
Days 15 and 28.  
• Time to first SpO 2 <88% that is sustained for at least 10 seconds during the 6MWT at 
Days 15 and 28.  
• Area under the SpO 2 curve (AUC) during the 6MWT measured at baseline, Day 15 and 
Day 28.  
• Change from baseline in PRO  scores  using  SGRQ , UCSD , A Tool to Assess Quality of Life 
(ATAQ) in IPF  (only subjects enrolled in Part B) , and the Borg Scale of Perceived 
Exertion questionnaire s and cough VAS at Days 15 and 28.  
• Change and percentage change from baseline in cardiopulmonary exercise testing 
parameters at D ay 29.  
• Change  and percentage change from b aseline in lung function, including FVC and DL CO 
at Day 28.  
• PK/PD relationship  in subjects receiving GBT440 from Baseline to Day s 15 and 28  
 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 33 
 
CONFIDENTIAL  
 4. STUDY POPULATION  
4.1. Inclusion Criteria  
All subjects must meet the following inclusion criteria:  
1. Able and willing to provide s igned informed consent to participate in this study . 
2. Documented diagnosis of IPF , as indicated in the ATS/ERS/JRS/ALAT 2011 guidelines . 
3. Adult male s or females aged 45 –80 years inclusive at randomization . 
4. Oxygen saturation (SpO 2) ≥88 % by pulse oximetry while breathing room  air at rest . 
5. Oxygen saturation (SpO 2) <88% and at least a 5% absolute decrease during the baseline 
6MW T which is sustained for at least 10 seconds . 
6. Able to walk a  total of at  least 1 00 meters at completion of the baseline  6MWT . 
7. Weight ≥ 40 kg 
8. Subject is seronegative for hepatitis A (IgM anti -HAV), hepatitis B surface antigen 
(HBsAg), hepatitis C antibody (anti -HCV), and human immunodeficiency virus antibody 
(anti-HIV)  within 3 month s of screening . 
9. Able, in the Inve stigator ’s opinion , to complete the 6MWT  unassisted at baseline and 
Day 15 and Day 28 and comply with the study procedures , including attend ing all 
assessment visits  and adhering  to all study requirements and restrictions.  
10. Male or female  of child bearing potential willing and able to use highly effective methods 
of contraception from study start to 3 months after the last dose of study drug . 
4.2. Exclusion Criteria  
Any subject  who meets one or more of the following criteria will be excluded  from 
participation:  
1. FEV1/FVC <70% 
2. Requires supplemental oxygen therapy at rest. 
3. History of other interstitial lung diseases including but not limited to radiation, drug 
toxicity, sarcoidosis, hypersensitivity pneu monia, bronchiolitis obliterans  or organizing  
pneumonia . 
4. History of clinically significant environmental exposure kn own to cause pulmonary 
fibrosis,  including but not limited to drugs (e.g. methotrexate or amiodarone), asbestos, 
beryllium, radiation and domestic birds . 
5. History of other medical condit ions that are known or may result in interstitial lung 
disease. For example, any connective tissue disease including but not limited to 
scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus and 
rheumatoid arthritis . 
6. AST, ALT or total Bilirubin >2 × ULN  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 34 
 
CONFIDENTIAL  
 7. Creatinine Clearance (CrCl) <30 mL/min/1.73 m2, calculated using the Modification of 
Diet in Renal Disease estimated Glomerular Filtration Rate (MDRD eGFR ). 
8. Significant polycythemia defined as hemoglobin value >18 mg/dL .  
9. ECG with a QTcF >450 ms (males) or QTcF >470 ms (females) .  
 If ventricular pacing is noted on ECG, then QTcF intervals will not be calculated  
10. Family or personal history of congenital long QT syndrome . 
11. Female who is breast -feeding or pregnant . 
12. Known current malignancy or current evaluation for a potential malignancy or h istory of 
malignancy within the past 2 years prior to screening , except for appropriately treated 
non-melanoma skin carcinoma, carcinoma in situ of the cervix, or Stage 1 uterine 
cance r. 
13. Subject has used any of the following therapies within 30 days of screening:  
 Any cytotoxic, immunosuppressive or cytokine -modulating therapy including but 
not limited to: azathioprine, bosentan , ambrisentan, cyclophosphamide, 
cyclosporine, etanercept, iloprost, infliximab, leukotriene antagonists, methotrexate, 
mycophenolate, tacrolimus  
 Imatinib mesylate, Interferon gamma -1b, tyrosine kinase inhibitors (excluding 
nintedanib ) 
14. Pulmonary hypertension requiring active therapy including but not limited to endothelin 
receptor inhibitors or PDE inhibitors (e.g., sildenafil, tadalafil ).  
 Note: intermittent use of a PDE inhibitor for erectile dysfunction may be allowed 
after approval by the Medical M onitor.  
15. Hospitalization due to an ex acerbation of IPF within 30  days of screening . 
16. Subject plans to begin or has commenced pulmonary rehabilitation within 30 days of 
screening  
 Subjects on a stable exercise regimen at screening or whose regimen, in the opinion 
of the investigator, is not expected to change at any time during the entire study will 
be considered eligible for the study  
17. Corticosteroids ( >10 mg per day of predni sone or an equivalent) within 30 days of 
screening.  
18. Current smoker (including use of eCigarettes or vaporizing ) or history of smoking 
within 3 months  from screening.  
19. Clinical evidence of active infection , including but not limited to bronchitis, pneumonia, 
sinusitis, urinary tract infection or cellulitis , within 14 days of screening . 
20. Active tuberculosis requiring treatment within the last 12  months . 
 Testing for latent tuberculosis is not required  
21. Currently  or, in the opinion of the investigator , soon to be listed for  lung transplant .  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 35 
 
CONFIDENTIAL  
 22. History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within 
6 months of screening includ ing but not limited to the following:  
 Unstable angina pectoris or myocardial infarction or elective coronary intervention  
 Congestive heart failure requiring hospitalization  
 Uncontrolled clinically significant arrhythmias  
23. Any condition possibly affecting dr ug absorption, such as previous surgery on the 
stomach or small intestine . 
24. Participated in another clinical trial of an investigational drug (or medical device) within 
30 days or 5 -half-lives,  whichever is longer, prior to s creening, or is currently 
partic ipating in another trial of an investigational drug (or medical device).  
25. Known hypersensitivity to any component of the study drug . 
26. Subject who, for any reason, is deemed by the investigator to be inappropriate for this 
study; or has any condition (such as  addictive or psychosocial issues)  which would 
confound or interfere with the evaluation of the safety, tolerability, or PK of the 
investigational drug; or is unable to comply with the study protocol.  
27. History of mental illness within the last 5 years, unle ss the subject fulfills one of the 
following conditions:  
 The subject has not required or been prescribed any psychiatric medication 
(including but not limited to antidepressants or anxiolytics) within 12 months before 
screening and, in the opinion of the i nvestigator, the subject is able and safe to 
participate in the study  
 The subject has been on a fixed regimen of psychiatric medications for at least 6 
months before screening and displays no sign of acute mental illness and, in the 
opinion of the investig ator, the subject is able and safe to participate in the study  
 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 36 
 
CONFIDENTIAL  
 5. STUDY PROCEDURES AND EVALUATIONS  
5.1. Subject Screening  
The subject must be willing and able to sign and date  the informed consent form (ICF) before 
any screening procedures or study -specific tests may be performed . The baseline 6MWT 
performed at screening must be performed within 7 days  of the Day 1 visit.  If the 6MWT 
falls outside of the 7-day window, it must be re peated  (the repeat may occur at the time of the 
Day 1 visit prior to any Day 1 visit assessments).  
All subjects who sign the informed consent will be given a unique study number. This 
number will be used to identify the subject throughout the clinical stud y and must be used on 
all study documentation related to that subject.  
The screening period for a particular subject commences at the point at which the subject 
undergoes the first study -specific screening assessment and must be completed  and evaluated 
(refer to  Appendix A ), prior to any Day 1  visit assessments . 
Subjects may be rescreened  up to two times , if deemed appropriate by the Principal  
investigator . The rescreening visit should not occur sooner than 10 calendar days after the 
failed screening visit.  
5.2. Avoidance of Pregnancy  
Women of Child -Bearing  Potential  
Pregnancy should be avoided by either absolute abstinence or the use of highly effective 
means of contraception ( refer to  Section  8.6) for th e duration of the study and a total period 
of 3 months  after the subject has taken the last dose of GBT440.  
Female subjects who become pregnant during the study will have study drug discontinued 
but continue in the study to complete all safety follow up as sessments ( refer to  Section 6.3). 
Women of Non Child -Bearing Potential  
Female subjects of  non-child -bearing potential are defined as; bilateral oophorectomy , 
hysterectomy  or post-menopausal females being amenorrhoeic f or at least  2 years . 
For female subjects who report surgical sterilization (i.e., hysterectomy and/or bilateral 
oophorectomy), surgical sterilization procedures should be supported  with clinical 
documentation and noted in the Relevant Medical History/Current Medical Conditions 
section of the CRF.  
Instructions for Male Subjects  
There is no information about effects that GBT440 could have on the development of the 
fetus  in humans.  Therefore, it is important that the partners of male subjects do not become  
pregnant durin g the entire study and for a total 3 months after the male subject has taken the 
last dose of GBT440.   
All male subjects should use the methods of contraception as outlined in Section 8.6 ).  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 37 
 
CONFIDENTIAL  
 5.3. Clinical Assessments   
Screening assessment s must be performed and evaluated prior to randomization  on Day 1 . 
This study has nine visits in total including the screening visit and patients will be enrolled 
for approximately 58 days from the time of randomization until the last study visit . The 
timing of the visits, associated visit windows and all assessments are outlined in  Appendix  A: 
Schedule of Study Assessments.  
5.3.1.  Medical History and  Demographic Data  
Medical history includes clinically significant diseases, surgeries, cancer history (including 
prior cancer therapies and procedures), inflammatory/autoimmune disease, smoking history, 
use of alcohol and drugs of abuse within the previous  year, and IPF-associated  conditions 
including but not limited to pulmon ary hypertension, familial IPF and gastroesophageal 
reflux disease.  Medical conditions that are a result of side effects from concomitant 
medications should be clearly defined and ente red into the eCRF .  
Any medical condition present at baseline  should be followed during the study and a change 
from the baseline status (intensity or frequency) should be reported as an adverse event if 
deemed clinically significant by the investigator ( refer to  Section 10). 
All concomitant medications (e.g., prescription drugs, over -the-counter drugs,  
herbal/homeopathic remedies, nutritional supplements) used by the patient within  30 days 
prior to the Screening  visit should be ente red on the Concomitant Medications eCRF. A start 
date should be entered for all medication items entered into the Concomitant Medications 
eCRF, including those medications used chronically.  
Demographic data will include age (date of birth), sex, and self -reported race/ethnicity.  
5.3.2.  Physical Examination  
A complete physical examination should include the following: an evaluation of the head,  
eyes, ears, nose, throat, and the cardiovascular, dermatological, musculoskeletal,  respiratory, 
gastrointestinal, and neurological systems. A rectal or pelvic examination  is not required. 
Any abnormality identified during screening should be recorded on the  eCRF . 
At subsequent visits, limited , symptom -directed physical examinations shoul d be performed. 
Changes from baseline abnormalities should be recorded in the patient notes.  New or 
worsened abnormalities should be recorded as adverse events on the Adverse  Event eCRF . 
Vital signs will include measurements of respiratory rate, pulse rate , body temperature, 
systolic and  diastolic blood pressure and SpO 2 by pulse oximetry. Blood pressure and SpO 2 
measurements should be taken while the patient is in a seated or semi -recumbent position, 
and resting  for at least 5 minutes . 
5.4. Laboratory Examinati on 
5.4.1.  Clinical Laboratory Studies  
It is the responsibility of the Investigator to assess the clinical significance of all abnormal 
clinical laboratory values as defined by the list of normal values on file for the local  clinical 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 38 
 
CONFIDENTIAL  
 laboratory.  All clinically sig nificant laboratory value abnormalities are to be recorded as 
AEs.  
For the purpose of this study, a clinically significant laboratory value will be any abnormal 
result that, in the judgment of the Investigator, is an unexpected or unexplained laboratory 
value or if medical intervention or corrective action is required . Any abnormal values that 
persist should be followed at the d iscretion of the Investigator.  
Please refer to  Appendix A Schedule of Study Assessments for all time points . 
5.4.1.1.  Hematology  
Hematology assessments will include red blood cells (RBCs) , hematocrit, hemoglobin, 
platelets and white blood cells ( WBCs ) with differential (basophils, eosinophils, neutrophils , 
monocytes and lymphocytes).  Reticulocyte count and serum e rythropoietin will also be 
collected .  
5.4.1.2.  Blood Chemistries  
Blood chemistry assessments will include measurement of albumin, bicarbonate, blood urea 
nitrogen (BUN), calcium, chloride , creatinine, creatine kinase, glucose, lactate 
dehydrogenase, magnesium, pho sphorus, po tassium, sodium, total protein , and uric acid.  
5.4.1.3.  Liver Function  
Liver function assessments will include measurements of serum alanine aminotransferase 
(ALT), aspartate amin otransferase (AST), alkaline phosphatase, gamma glutamyl transferase 
(GGT), and total  bilirubin (direct and indirect).  
5.4.1.4.  Urinalysis  
Urine will be assessed for color and appearance.  Dipstick analysis for specific  gravity, pH, 
protein, glucose, ketones and occult blood and micro scopic analysis (RBCs, WBCs, bacteria 
and casts) will be performed.  
5.4.1.5.  Electrocardiograms  
12-lead ECGs should be performed after the subject has been resting in a supine or semi -
recumbent position for at least 5 minutes and prior to all other non -PRO assessme nt. The 
ECGs will be collected in triplicate. Three separate recordings approximately 1 minute apart 
should be performed. All three tracings must  be stored at the study site.  If ventricular pacing 
is noted on ECG, then QTcF intervals will not be calculated . 
5.4.1.6.  Other Clinical Laboratory Tests  
Screening tests  will include serology for hepatitis A (IgM anti -HAV), hepatitis B surface 
antigen (H BsAg ), hepatitis  C (HCV) and  HIV-1/0/2 antibodies  if there is no documented 
testing results within 3 month s of screening . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 39 
 
CONFIDENTIAL  
 For women of child bearing potential, a p regnancy test ( serum HCG) will be performed  at 
screening  and u rine pregnancy testing will be performed during the  study . If the urine 
pregnancy test is positive the result must be confirmed with a serum pregnancy te st. 
Coagulation (Panel) including PT, PTT and INR will be collected  at screening  and Day  28. 
5.5. Disease Related Evaluations  
5.5.1.  Spirometry and Diffusing Capacity of the Lung for Carbon Monoxide 
(DL CO)  
All equipment, procedures, and personnel qualifications for t he assessment of lung function 
should  be based on  the recommendations  of the Ameri can Thoracic Society ( ATS 2005 ) and 
will be performed at each site using local equipment  and procedures.  
Spirometry measurements will include FVC , FEV 1, DL CO and other measures per the site’s 
local practices . Post -bronchodilator assessments will not be performed.  
DL CO will be measured at each site by determining the diffusing/transfer capacity of the lung  
for carbon monoxide.  
Spirometry and DL CO should be performed at each scheduled visit at approximately the same 
time of day (e.g. in the morning) and before the 6MWT, if scheduled on the same visit day.  
Local reports from the spirometry and DL CO testing will be stored on site.  
5.5.2.  Oxygen Saturation  
During screening and with all scheduled vital sign assessments resting , room air oxygen 
saturation (SpO 2) will be measured by pulse oximetry  (provided by the Sponsor) whilst the 
subject is seated and resting  for at least 5  minutes . Before recording the SpO 2 value in the 
eCRF the study staff should ensure the measurement is stable, which may require continuous 
or repeated measurements and ensuring the subject is resting.  
SpO 2 will be also be collected at baseline , during and following  completion of the 6MWT 
and cardio -pulmonary exercise testing . 
5.5.3.  6-Minute Walk Test (6MWT)  
Functional exercise capacity will be evaluated at Baseline and Days  15, 28 and 58  using the 
6-minute walk test . The 6MWT will be performed  without the subject using supplementary 
oxygen . Oxygen may be used at any time during the 6MWT, if in the opinion of the 
Investigator or testing technician it is required for safety reasons. The 6MWT should then be 
stopped.  
The baseline  6MWT performed at screening must be  performed within 7 days  of the Day 1 
visit.  If the 6MWT falls outside of the 7-day window, it must be repeated (the repeat may 
occur at the time of the Day 1 visit prior to any Day 1 visit assessments).  
Guidelines developed by the ERS/ ATS will be used  for conducting the test and interpreting 
the results ( ATS 2002  and Holland  2014 ). Instructions for the conduct of the 6MWT will be 
provided in a separate manual.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 40 
 
CONFIDENTIAL  
 The 6MWT should be performed at eac h scheduled visit at approximately the same time of 
day (e.g. in the morning) and after spirometry and DL CO assessments (if scheduled on the 
same Visit day).  
As part of the 6MWT , SpO 2, heart rate and the Borg dyspnea scale will be measured at the 
following  time points: prior to starting the test, during the test, at completion of the test, 
1 minute and 2 minutes after test completion.  
For safety reasons, all patients should be clinically stable prior to performing the 6MWT . 
Absolute contraindications  to the 6MWT include unstable angina or myocardial infarction 
during the previous month.  
Relative contraindications  to participation in the 6MWT include:  
• Resting heart rate >120 or <60 beats per minute  
• Systolic blood pressure >180 mmHg  
• Diastolic blood pressure >100 mmHg  
5.5.4.  Cardiopulmonary Exercise Testing (CPET)  
Symptom -limited cardiopulmonary exercise testing using a bicycle ergometer will be 
performed  on Day 2 and Day 2 9. At baseline and during the exercise period  the collected 
data will include but is not limited to:  SpO 2 and arterial blood gas es, VO 2 max, ventilation 
and lactate threshold s. Guidelines developed by ATS and American College of Chest 
Physicians will be used for conducting the test and inter preting the results ( ATS 2003 ). 
Instructions for the conduct of the CPET will be provided in a separate manual.  An arterial 
line placement will be part of the CPET  procedure . If the subject refuses arterial line 
placement they may still undergo the CPET assessments without the arterial l ine. 
Agreement to undergo the  CPET is not required  for entry into the study ; but participation is 
strongly encouraged.   
5.5.5.  Patient Reported Outcome (PRO) Measures  
PRO assessments  should be self -administered by the subject, using the paper questionnaires 
provi ded by the Sponsor, at the investigational site prior to all other non -PRO assessments  
(except in cases when the screening 6MWT is being repeated on Day 1 prior to any Day 1 
visit assessments)  and before the patient receives any disease -status information during that 
assessment.  They  will be administered as indicated in the schedule of assessments ( Appendix 
A).  
5.5.5.1.  St George’s Respiratory Questionnaire (SGRQ)  
The SGRQ is a symptom -specific 2 -part, patient self -administered questionnaire that assesses 
shortness of breath while doing a variety of activities of daily living . This questionnaire 
comprises three domains: symptoms, activity and impact . Items are assessed on various 
response scales, including a 5 -point Likert scale and True/False scale. The SGRQ has a recall 
specification of 4 weeks.  Paper q uestionnaires will be provided to sites prior to subject  
enrollment.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 41 
 
CONFIDENTIAL  
 5.5.5.2.  University of California, San Diego Shortness of Breath Questionnaire 
(UCSD)  
The UCSD is a 24-item assessment of breathlessness associated with various activities of 
daily living. The response for each item is measured on a 5-point Likert scale from 0 (none at 
all) to 5 (m aximal or unable to perform) . Paper q uestionnaires will be provided  to sites prior 
to subject enrollment.  
5.5.5.3.  Borg Dyspnea Scale  
The Borg Dyspnea scale is a 1 -item assessment , self-administered by the patient 
administered  as part of the  6 MWT.  The instrument will be used to assess dyspnea from the 
patient’s perspective. The S cale ranges from 0 (Nothing at all) to 10 (Absolute 
maximum/Highest possible). Refer to the  Procedure  Manual  for a copy of the assessment.  A 
paper scale will be provided  to sites prior to subject enrollment.  
5.5.5.4.  A Tool to Assess Quality of Life (ATAQ) in IPF  
ATAQ questionnaires will be administered  in Part B of this study . Paper questionnaires will 
be provided to sites prior to subject enrollment in Part B of the trial.  
5.5.5.4.1.  A Tool to Assess Quality of Life (ATAQ) in IPF Symptoms Questionnaire   
The ATAQ -IPF Symptoms Questionnaire is an IPF specific, self -administered questionnaire 
that assesses the subject’s disease symptoms across three domains (physical activity, cough, 
and energy level) and a set of questions pertaining to oxygen  use. Items ar e assessed using a 
Likert scale with a 24 -hr recall period.  
5.5.5.4.2.  A Tool to Assess Quality of Life (ATAQ) in IPF Impacts Questionnaire  
The ATAQ -IPF Impact Questionnaire is an IPF specific, self -administered questionnaire that 
assesses how IPF affects the subjec ts’ quality of life.  Items are assessed using a Likert scale 
with a one week  recall period.  
5.5.5.5.  Visual Analog Scale (VAS) for Cough Severity  
Cough will be assessed using a VAS in which the subject will indicate the severity of their 
cough by drawing  a mark on a 100 mm scale, which  ranges from 0 - “no cough” to 100  m - 
“worst cough severity”. A paper scale will be provided  to sites prior to subject enrollment.  
5.5.5.6.  End of Study Questionnaire  
The End of Study Questionnaire  is an 8-item survey to evaluate the subjects'  experience 
while on the study including symptoms, changes in oxygen saturation and use . This is a self-
administered  survey to be completed during  the Day 58 visit. The survey is to be completed 
by subjects enrolled under  Part B of the trial . A paper End of Study Questionnaire will be 
provided to the sites prior to subject enrollment in Part B. Subject responses will be entered 
in the eCRF by the site. At completion of the study the paper questionnaires will be returned 
to the Sponsor . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 42 
 
CONFIDENTIAL  
 5.6. Pharmacokinetic  Samples  
Plasma and whole blood concentrations of GBT440 will be measured  using validated LCMS 
methods . Instructions for sample collection, processing and shipment are described in a 
separate lab manual.  Up to nine PK samples will be collecte d at the following times  (also 
refer to the  Schedule of Assessments,  Appendix A ): 
 During Treatment Period  
Pre-dose 2 hrs ± 15 min post -dose 
Day 1 (Visit 2)  X X 
Day 2 (Visit 3)  X*   
Day 8 (Visit 4)  X   
Day 15 (Visit 5)  X   
Day 28 (Visit 6)  X  X 
 During Follow -Up Period  
Day 45 (Visit 8)  X 
Day 58 (Visit 9)  X 
* On Day 2 the PK sample s hould be drawn 24 hours (± 2 hours ) after the Day 1 dose and prior to receiving 
the Day 2 dose . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 43 
 
CONFIDENTIAL  
 6. EARLY DISCONTINUATION OF STUDY OR INDIVIDUAL SUBJECTS  
6.1. Early Discontinuation of the Study and /or Site 
The Sponsor has the right to terminate this study at any time.  Reasons for terminating  the 
study may include, but are not limited to :  
• Incidence or severity of adverse events in this or other studies indicating a potential 
health hazard to subjects.  
• Unsatisfactory subject recruitment e.g. excessively slow  
• Poor protocol adherence  
• Incomplete or inaccurate data recording  
• Poor compliance with the Inte rnational Conference on Harmoni sation (ICH ) guidelines 
for Good Clinical Practice (GCP)  
In any instance of early discontinuation  of the study, the Sponsor will notify, in writing, the 
investigators, regulatory authorities and ethics committees, and will specify the reason (s) for 
termination.   
6.2. Earl y Discontinuation of Individual subject s 
Reasons for s ubject  withdrawal from the study may include but are not limited to any of the 
following reasons:  
• Subject withdrawal of consent  
• Discretion of the Investigator , if it is deemed not safe, or in the subjec t’s best interest, 
to continue  
• SMC recommendation  
• Subject  is lost to follow -up 
The date and reason for discontinuation s hould be documented in the eCRF .  
Subjects who discontinue the study should return to the site to complete the Visit 8 (Day 45)  
assessments within 2 weeks ( ± 7 days) from the date of discontinuation . 
6.3. Study Treatment Discontinuation  
Subjects should discontinue study drug for any of the following reasons:  
• Malignancy: not including local and non -serious basal or squamous cell skin can cer 
• Pregnancy  
• Anaphylaxis, anaphylactoid or serious hypersensitivity reaction  
• Use of any medication ( refer to  Section 8.5), intended to chronically treat IPF, other 
than those documented at screening  
• Adverse event which in the opin ion of the investigator precludes the subject from 
safely continuing in the study  
• Pulmonary rehabilitation started at any time from screening until the end of the study  
• Subject is noncompliant with study requirements  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 44 
 
CONFIDENTIAL  
 The date and reason for discontinuation  should be documented in the eCRF . 
Subjects who discontinue study drug should continue in the study to complete all scheduled 
assessments . 
Those subjects who are unwilling or unable to complete all remaining study assessments, 
should return to the study si te 2 weeks  (+ 7 days ) after the last dose of study drug  to complete  
the Visit 8 ( Day 45 ) assessment s. 
In this way all subjects will be assessed at least 5 half-lives  after the last dose of study drug  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 45 
 
CONFIDENTIAL  
 7. STUDY DRUG  AND ACCOUNTABILITY  
7.1. Study Drug  
7.1.1.  Physical Description  
GBT440 is synthetic small molecule bearing the chemical name 2 -hydroxy -6-((2-(1-
isopropyl -1H-pyrazol -5-yl) pyridin -3-yl) methoxy)  benzaldehyde. The chemical formula is 
C19H19N3O3 and the molecular weight is 337.38.  
7.1.2.  Formulation  
GBT440 Capsules:  GBT440 will be provided as 300 mg  capsules which contain GBT440 
drug substance in Swedish orange, opaque, size 0, hypromellose  capsules  along with several 
formulation excipients including hypromellose, microcrystalline cellulose, lactose 
monohydrate, croscarmellose sodium and magnesium stearate . All the excipients used for the 
formulation are FDA II D (Inactive Ingredients Database ) listed.  
Placebo Capsules:  The placebo capsules contain microcrystalline cellulose  in Swedish 
orange, opaque, size 0, hypromellose capsules. All the excipients used for the formulation are 
FDA II D (Inactive Ingredients  Database ) listed. The placebo capsules do not contain any 
GBT440 drug substance.  
7.1.3.  Packaging and Labeling  
GBT44 0 and p lacebo capsules will be supplied to the site in 100 mL high-density 
polyethylene (HDPE) bottles  induction sealed with child -resistant polypropylene (PP) screw 
caps bottles of 30 capsules . 
An unblinded study pharmacist will prepare daily doses of study drug dispensed into 30 mL 
high-density pol yethylene (HDPE) bottles with child -resistant polypropylene (PP) screw 
caps. Packaging and labeling of each bottle and its contents are specific to each subject in the 
study and is based on the treatment group assignment at randomization.  
Each 30 mL bottle  (or dose) is packaged individually with 3 capsules of active or placebo or 
both specific to each subject ’s assigned treatment group . 
7.1.4.  Supply  
GBT or their representative will supply the packaged and labeled drug product  to the 
investigational sites.  Additional details are provided in the pharmacy manual.  
7.1.5.  Storage and Handling Procedure  
All study medications will be stored at controlled room temperature between 15°C to 25°C 
protected from light in the storage area of the investigational site pharmacy, w hich is a 
secure, temperature controlled, locked environment with restricted access.  
No special procedures for the safe handling of GBT440 or placebo are required.  The Sponsor 
will be permitted upon request to audit the supplies, storage, dispensing proced ures and 
records provided that the blind of the study is not compromised.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 46 
 
CONFIDENTIAL  
 7.2. Drug Accountability  
In accordance with GCP, the Investigational Site will account for all supplies of GBT440  and 
placebo.  Details of receipt, storage, assembly and return will be rec orded.  
All unused supplies of GBT440 and placebo will either be destroyed by the investigational  
site or returned to the study Sponsor or designee at the end of the study in accordance with 
instruction s from  the Sponsor.  
Additional details are provided i n the pharmacy manual . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 47 
 
CONFIDENTIAL  
 8. DOSAGE AND TREATMENT ADMINISTRATION  
8.1. Treatment Regimen  
GBT440 and p lacebo will be administered orally each day  for 28 days.  GBT 440 will be 
administered as 300 mg capsules. Placebo will be provided as capsules matching the 
GBT440 capsules.  Subjects randomized to the  following treatment groups will receive : 
Part A:  
• GBT440 900 mg:  3 GBT440 300 mg capsules.  
• GBT440 600 m g: 2 GBT440 300 mg capsules and  1 placebo capsule.  
• Placebo:  3 placebo capsules.  
Part B:  
• GBT440 1500 mg:  5 GBT440 300 mg capsules  
• GBT440 600 mg:  2 GBT440 300 mg capsules and  3 placebo capsule.  
• Placebo:  5 placebo capsules.  
Instructions for Administration of Study Drug: 
• Self-administered  by subject in the morning  
- except  on study visit days when the subject must not take study drug. It will be 
administered at the site after completion of scheduled  assessments.  
• May be taken with or without food  
• May be t aken with water or other non -alcoholic beverage  
Subjects must be instru cted not to take study drug the day of their scheduled visits ( refer to  
Appendix  A). Study drug will be administered at the site on these days , after completion of 
all the assessments scheduled for that visit.  
8.2. Study Drug Dispensing  
Study drug will be dispensed to subjects on study Days 2, 8 and 15 as indicated in the 
schedule of assessments ( refer to  Appendix A ). Each daily dose will be dispensed into 
separate containers and provided to the sub ject at the study site.  
If a dose reduction is required subjects must return to the study site for study drug to be 
re-dispensed. Subjects must return any remaining study drug and all study drug containers to 
the site where they will be destroyed as instru cted by the Sponsor.  
8.3. Dose Modification  
Modification of study drug dosing may be considered if, in the opinion of the study 
Investigator, the AE may be related to study drug and it would be unsafe for the subject to 
continue receiving their current dose of study drug. The Investigator’s assessment of AE 
relatedness should take into account the toxicity profile of all concomitant medications 
including pirfenidone and nintedanib . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 48 
 
CONFIDENTIAL  
 Not all AEs require study drug modifications and may be managed as determined  by the 
Investigator.  
The Sponsor ’s Medical Director should be contacted prior to any change in dosing.  
8.3.1.  Dose Adjustment  
Dose adjustments  may be initiated by the Investigator based on their assessment of the 
associated AE severity and overall subject safety  and in discussion with the Sponsor ’s 
Medical Director . 
The Investigator , in discussion with the Sponsor’s  Medical Director,  may cho ose to: 
• Change dosing frequency,  to one capsule 3 times per day   
• Reduce the total daily dose   
A reduction in dose should be by one active study drug capsule . Dose reductions will require 
the subject to return to the study site for the unblinded pharmacist to dispense new study drug 
capsules.  Subjects will continue to take 3 capsules per day  if in P art A and 5  capsules per day 
if in Part B of the study . 
A second dose reduction by another one active study drug capsule may be initiated if deemed 
necessary by the Investigator  and based on a safety assessment of the subject . The timing of 
the second dose reduction will be based on the Investigator’s clinical assessment and in 
discussion with the Sponsor ’s Medical Director .  
The Investigator must make every effort to restart the dosing regimen assigned to the subject 
at rando mization , as soon as it is safe to do so .  
8.3.2.  Dose I nterruption  
Dose interruption may be initiated by the Investigator based on the ir assessment of the 
associated AE severity and overall subject safety  and in discussion with the Sponsor’s  
Medical Director .  
Re-initiation of dosing will be based on the Investigator’s clinical assessment and in 
discussion with the Sponsor ’s Medical Director . Dosing should  be restarted at the dose 
assigned to the subject at randomization.  
The Investigator must make every effort t o restart the dosing regimen assigned to the subject 
at randomization as soon as it is safe to do so.  
Study treatment may be discontinued due to an AE if , in the opinion of the investigator, it is 
unsafe for the subject to continue receiving study drug . Patients who discontinue study drug 
should remain in the study and complete all scheduled assessments ( refer to  Section 6).  
8.3.3.  Pirfenidone or Nintedanib Background Therapy  
If, in the opinion of the Investigator, the subject  experience s significant side effects,  judged 
to be related to pirfenidone or nintedanib  therapy , treatment of symptoms and/or dose 
modifications of these medications are allowed .  
The decision to modify pirfenidone or nintedanib  dosing is ultimately the responsibili ty of 
the investigator . Any modifications to dosing will  be managed by the Investigator throughout 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 49 
 
CONFIDENTIAL  
 the study, taking in to account the Prescriber Information (USPI) of the drugs and past 
history of care from the subject’s IPF health care provider and must be entered into the 
eCRF . 
8.4. Treatment Overdose  
To date no events of overdose have been reported. Based on the mechanism of action of 
GBT440, the result of an overdose might include, but is not limited to, increased severity of 
previously reported associated adverse events or decrease d oxygen delivery to tissues  (refer 
to Section 1 ). In the event of a medical emergency due to suspected GBT440 overdose  the 
Medical Monitor  should be contacted as soon as possible .  
8.5. Concomitant Medications  
A concomitant medication is defined as any prescription or over-the-counter preparation, 
inclu ding vitamins and supplements.  
In the interests of subject safety and accept able standards of medical care the Investigator 
will be permitted to prescribe treatment(s) at his/her discretion.  For all randomized subjects, 
all administered concomitant medications from signing the informed consent until the last 
study visit must be recorded in the subjects’ eCRF . 
All prior and concomitant medications that have been reported , will be coded  using the 
current version of the WHO Drug Dictionary . 
8.5.1.  Permitted therapy  
Use of the following therapies is allowed during the study:  
• Pirfenidone, nintedanib or N -acetylcysteine (NAC)  for the treatment of IPF   
- If at the time of screening, the dose has been stable for at least 1 month prior to 
screening and with no anticipated need for dose adjustments during the study.  
• Corticosteroids:  
- if the dose at screening is ≤10 mg per day of prednisone (or an equivalent) and 
has been stable for at least 2 weeks prior to screening and with no anticipated 
need for dose adjustments, including reductions in dose, during the study.  
- Use of corticosteroids for other  non-IPF related reasons, including but not limited 
to intra -articular or intramuscular delivery, should be discussed with the medical 
monitor before administering.  
- Maintenance therapy for other medical conditions listed in the subject’s medical 
history a t the time of screening . 
Medications such as acetaminophen, non -steroidal anti -inflammatories and routinely 
taken  dietary supplements, including vitamins are allowed at the discretion of the 
investigator and provided that the medications have no discernabl e impact on the study . 
8.5.2.  Restricted Therapies  
Subjects  should not take the following medications within 14 days prior to screening and 
during the entire stud y:  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 50 
 
CONFIDENTIAL  
  Strong inducers of CYP3A4/CYP3A5, CYP2B6, CYP2C9 and CYP2C19 (refer to  
Appendix B ; these medications may decrease the blood concentration of GBT440)  
 Herbal medications (e.g., St. John’s Wort)  
The following medications should be used with caution :  
 CYP3A4 substrates with a narrow therapeutic index ( refer to  Table 1; GBT440 may 
increase the plasma concentration of these medications ) 
Table 1 CYP Substrates with Narrow Therapeutic Range  
CYP Enzymes  Substrates with  Narrow Therapeutic Range  
CYP3A4  Alfentanil, astemizole, cisapride, cyclosporine, dihdroergotamine, 
ergotamine, fentanyl, pimozide, quindine, sirolimus, tacrolimus, 
terfenadine  
Note that this is not an exhaustive list.  For an updated listed, see the following link:  
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabelin
g/ucm093664.htm#4  
Substrates with narrow therapeutic range refers to drugs whose exposure -response relationship indicates 
that small increases i n their exposure levels by the concomitant use of CYP  inhibitors may lead to serious 
safety concerns.   
Adapted from:  FDA DRAFT Guidance for Industry: Drug Interactions Studies -Study Design, Data 
Analysis, Implications for Dosing, and Labeling Recommendatio ns. February 2012.  
8.5.3.  Therapies for T reatment of IPF  
Therapies, other than those used at the time of screening, for the treatment of IPF are not 
allowed.  
If in the opinion of the Investigator an escalation in therapy for IPF is required then study 
drug should be discontinued and the subject should complete all remaining scheduled 
assessments ( refer to  Section 6.3). 
8.6. Fertility/Contraceptive Requirements  
8.6.1.  Acceptable Forms of Contraception  
Highly effective methods of birth control are  defined as those which result in a low failure 
rate (i.e. less than 1% per year) when used consistently and correctly.  
• Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation:  
- Oral 
- Intravaginal  
- Transd ermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation:  
- Oral 
- Injectable  
- Implantable  
Note: Hormonal contraception must be supplemented with a barrier method (preferably male 
condom).  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 51 
 
CONFIDENTIAL  
 • Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomised partner. Note that vasectomised partner is a highly effective birth 
control method provided that partner is the sole sexual partner of the woman of child 
bearing potential trial particip ant and that the vasectomised partner has received 
medical assessment of the surgical success.  
• Sexual abstinence. Sexual abstinence is considered a highly effective method only if 
the subject is refraining from heterosexual intercourse during the entire pe riod of risk 
associated with the study treatments. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the clinical trial and the preferred and usual 
lifestyle of the subject.  
For male subjects:  
• Men must agree to use two acceptable methods of contraception, at least one of which 
must be a barrier method (e.g., spermicidal gel plus condom) for the entire duration of 
the study , and for 3 months following last study drug administration.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 52 
 
CONFIDENTIAL  
 9. RANDOMIZATION PROCEDURE  
Subject r andomization will be carried out central ly through an Interactive Response System 
(IxRS). 
In Part A , eligible subjects will be randomized 1:1:1 to either: 9 00 mg GBT440, 600 mg 
GBT440 or p lacebo , respectively . A total of approximatel y 18 subjects will be randomized .  
In Part B,  up to an additional  15 subjects will be enrolled and randomized 3:1:1 to either: 
1500  mg GBT440, 600 mg GBT440 or placebo  to further  characterize the safety , tolerability 
and potential treatment response of GBT440.  In the eventuality that one treatment arm is 
discontinued subjects may be randomised 1:1 to the remaining  study treatment group or 
placebo.  
Randomization  will be stratified by background IPF therapy  used at the time of entry into the 
study , that is pirfeni done or nintedanib . 
9.1. Blinding  
The GBT440 and placebo oral capsules will be matched for shape, size and color.  
If at any time during the study a decision about a subject’s medical condition requires 
knowledge of the treatment assignment, the study blind may be broken (through IxRS ) for 
that specific subject only.  If in the opinion of the Investigator, there is no impact on patient 
safety,  the Investigator is encouraged to contact th e Sponsor’s Medical Director  prior to 
unblinding. The reason for unblinding must be  documented in the  appropriate section of the 
eCRF .  
At the study site , only t he Principal Investigator should be unbli nded . If, in the Investigator’s 
opinion , and for the s afety of the subject other study site personnel are required to be aware 
of the treatment assignment , the Investigator  will ensure that the minimum number of 
personnel are informed.  
The SMC must be informed by the Sponsor ’s Medical Director  of any case of unblinding . 
Additionally, the SMC may unblind individual treatment assignment for further safety 
evaluation at their discretion.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 53 
 
CONFIDENTIAL  
 10. SAFETY ASSESSMENTS  
GBT440 is not an approved drug and as a result,  the entire safety profile is not known at th is 
time. This Phase II study will contribute to the understanding of the safety profile for 
GBT440  and for its use in IPF patients.  
10.1. Safety Monitoring Committee  (SMC)  
The Safety Monitoring Committee (SMC) consisting of the Sponsor’s Medical Director , one 
Independent Physician  with clinical IPF expertise and one Independent  Physician with 
clinical trial experience. The SMC, along with the CRO’s statistician and data manager, will 
review the safety data throughout the study .  
The SMC may meet at any time during the study to review blinded or unblinded data when 
deemed necessary  by the SMC .  
In Part A, t he SMC will initially convene to review all available safety data after 
approximately 9  randomized subjects have completed the Day  15 visit. The SMC will also 
convene to review all available safety data aft er approximately 18  subjects have completed 
the Day 15 visit. I f the SMC does not identify any clinically significant safety concerns the 
Sponsor will randomise  up to an additional 15 subje cts, to three study treatment arms (1500 
mg GBT440, 60 0 mg  GBT440 or placebo) to better characterize the safety, tolerability 
and/or potential treatment response of GBT440.  
In Part B, the SMC will initially convene to review all available safety data after 
approximately 9  randomized subjects have completed the Day 15 visit. The SMC will also 
convene to review all available safety data after approximately 15  subjects have comp leted 
the Day 28 visit. At this time,  the SMC will review safety data from all subjects, in Parts A 
and B, who have received at least one dose of study drug.  
Details of the SMC are described in a separate charter.  
10.2. Adverse Events  (AE)  
An AE is defined as an y untoward medical occurrence in a ny subject enrolled in a clinical 
investigation administered a pharmaceutical product  regardless of causal attribution.  
An AE can therefore be any unfavorable and /or unintended sign, symptom, or disease 
temporally associat ed with the use of an investigational product, whether or not it is thought 
to be related to the investigational product. In addition to new events, any increase in the 
severity or frequency  of a pre -existing condition that occurs is considered an AE. This  
includes any side effect, injury, tox icity or sensitivity reaction.  Subjects will be monitored 
throughout the study for AEs, from the time informed consent is obtained until the last study 
visit (Day 58). Reporting of AEs prior to randomization should onl y include SAEs or AEs 
resulting from any protocol related interventions.  
Adverse events that are identified at the last assessment visit as specified in the protocol must 
be recorded in the  eCRF. All events that are ongoing at this time will be recorded  as ongoing 
on the eCRF. All (both serious and nonserious) AEs must be followed until they are resolved 
or stabilized, or until reasonable attempts to determine resolution of the event are exhausted. 
The investigator should use his/her discretion in orderi ng additional tests as necessary to 
monitor the resolution of such events.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 54 
 
CONFIDENTIAL  
 All reported AEs will be coded using the current version of the Medical Dictionary for 
Regulatory Activities (MedDRA).  
The procedures specified in Section 10.7 are to be followed for reporting  SAEs.  
10.3. Recording Adverse Events  
Adverse events are to be recorded on the AE eCRF. The following information will be 
recorded:  
• Whether o r not the AE is an SAE ( Section 10.4.1 ) 
• AE severity (Section 10.4.2 ) 
• AE relationship to investigational product ( Section 10.4.4 ) 
• Action taken , includin g but not limited to none, study drug dose modification  or 
discontinu ation, required concomitant medication, required procedure, or other  
• Outcome - recorded as : event resolved, resolved with sequelae, ongoing, or death . 
10.4. Assessment of Adverse Events  
The investigator will assess each AE for seriousness, severity , and relationship to study drug . 
10.4.1.  Serious Adverse Event (SAE)  
The investigator is responsible for determining whether an AE meets the definition of an 
SAE. An SAE is any AE occurring from signing of the informed consent form (ICF) until the 
end of the study (Day 58) that results in any of the following outcomes:  
• Death 
• Life-threatening  
- i.e. an AE that places the subject at immediate risk of death   
• Inpatient  hospitalization  or prolongation of  existing hospitalization  
• A persistent or signi ficant disability or incapacity  
- i.e. a substantial disruption in the subject’s ability to conduct normal life functions  
• A congenital anomaly or birth defect  in a neonate or infant born to a mother exposed 
to study drug  
• Significant medical events that , in the opinion of the investigator,  may jeopardize the 
subject or may require medical or surgical intervention to prevent any of the 
outcomes listed in this definition.  
SAEs will be reported to the CRO’s Drug Saf ety Department within 24  hours of the 
investigator, designee, or site personnel’s  knowledge of the event. Refer to “Reporting 
Serious Adverse Events” ( Section 10.7) for details.  
Note : Hospitalization is not considered to be an SAE  if a subject has a hospitalization or 
procedure (e.g. elective surgery) during the study, that was scheduled prior to the subject 
entering the study (i .e. before the subject signed the inf ormed consent) for a pre -existing 
condition (i.e. one that occurred before the study). However, if the event/condition worsens 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 55 
 
CONFIDENTIAL  
 during the study, it must be reported as an AE (or SAE, if the event/ condition results in a 
serious outcome such as hospitalizat ion). 
10.4.2.  Protocol -Defined Events of Special Interest  
An adverse event of special interest (AESI) is any AE occurring from signing of the 
informed consent form (ICF) until the end of the study (Day 58) that results in: 
 An alle rgic reaction/hypersensitivity:  Grade 2 or higher (as defined by NCICTC 
Version 4.03)  
AESIs will be reported to the CRO’s Drug Safety Department within 24  hours of the 
investigator, designee, or site personnel’s  knowledge of the event. Refer to Section 10.7 for 
details.  
10.4.3.  Severity of Adverse Events  
The severity of an event describes the degree of impact upon the subject and/or the need for 
medical care necessary to treat th e event.  Adverse events reported for subjects participating 
in this study will be graded using the National Cancer Institute’s  (NCI) Common 
Terminology Criter ia for Adverse Events (CTCAE), Version 4.03  
The Investigator will grade the severity of each AE us ing, when applicable, the NCI CTCAE, 
version 4.03. For AEs not included  in the NCI -CTCAE Version 4.03 , the c riteria outlined in 
Table  2 should be used as a g eneral guideline.  
Table  2 Grading for Adverse Events not Covered  in the NCI -CTCAE  
 
Severity  Description  
Grade 1 – Mild  Asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated  
Grade 2 – Moderate  Minimal, local or noninvasive intervention indicated; limited age -
appropriate instrumental activities of daily living (ADL)  
Grade 3 – Severe  Medically significant but not immediately life threatening; 
hospitalization or prolongation of hospitalization indicated; 
disabling; limiting self -care ADL.  
Grade 4 – Life-threatening  Life-threatening consequences; urgent intervention indicated  
Grade 5 – Fatal  Death  
ADL  = activities of daily living; NCI -CTCAE = National Cancer Institute -Common Terminology Criteria for 
Adverse Events . 
10.4.4.  Relationship to Study Drug  
The relationship of an AE to the investigational product should be determined  by the 
Investigator according to the following definitions:  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 56 
 
CONFIDENTIAL  
 • Not Related:  Evidence exists that the adverse event has an etiology other than the 
study drug (such as a preexisting condition, underlying disease, intercurrent illness, or 
concomitant medication).  
• Possibly/Probably Related:  A temporal relationship exists between the event onset 
and administration of the study drug.  It cannot be readily explained by the subject’s 
clinical state or concomitant therapies and appears with some degree of certainty to 
be related based on t he known therapeutic and pharmacologic actions of the drug.  In 
case of cessation or reduction of the dose, the event abates or resolves and reappears 
upon rechallenge.  It should be emphasized that ineffective treatment should not be 
considered as causally related in the context of adverse event reporting.  
These criteria in addition to good clinical judgment should be used as a guide for determining 
the causal assessment.  If it is felt that the event is not related to study drug therapy, then an 
alternative explanation should be provided.  
10.4.5.  Unexpected Adverse Reactions  
An adverse reaction is ‘unexpected’ if its nature and severity are not consistent with the 
information about the  study drug : 
• In the case of a product with a marketing authorization , in the summar y of product 
characteristics for that product . 
• In the case of any other IMP, in the Investigator’s Brochure relating to the trial in 
question .  
10.5. Reporting Adverse Events  
10.5.1.  Diagnosis versus Signs and Symptoms  
If known, a diagnosis should be recorded on the eCR F rather than individual signs and 
symptoms (e.g. , record only liver failure or hepatitis rather than jaundice, asterixis, and 
elevated transaminases).  However, if a constellation of signs  and/or symptoms cannot be 
medically characterized  as a single diagnosis or syndrome at the time of reporting, each 
individual event should be recorded as an AE or SAE on the eCRF.  If a diagnosis is 
subsequently established, it should be reported as follow -up information  and the diagnosis 
entered in the e CRF . 
10.5.2.  Adverse Events Occurring Secondary to Other Events  
In general, AEs occurring secondary to other events (e.g. , cascade events or clinical 
sequelae) should be identified by their primary cause.  For example, if severe diarrhea is 
known to have resulted i n dehydration, it is sufficient to record only diarrhea as an AE or 
SAE on the eCRF .  
However, medically significant AEs occurring secondary to an initiating event that are 
separated in time should be recorded as independent events on the eCRF.  For example , if a 
severe gastrointestinal hemorrhage leads to renal failure, both events should  be recorded 
separately on the eCRF . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 57 
 
CONFIDENTIAL  
 10.5.3.  Persistent or Recurrent Adverse Events  
A persistent AE is one that extends continuously, without resolution between subject  
evaluation time points . Such events should only be recorded once in the eCRF unless their 
severity increases.  If a persistent AE becomes more severe, it  should be recorded again on 
the Adverse Event  eCRF.   
A recurrent AE is one that occurs and resolves between subjec t evaluation time points and 
subsequently recurs.  All recurrent AEs should be recorded on an Adverse Event eCRF.  
10.5.4.  Abnormal Laboratory Values  
Only clinically significant laboratory abnormalities that require active management will be 
recorded as AEs or SAEs on the eCRF (e.g. abnormalities  that require study drug dose 
modification, discontinuation of study treatment, more frequent follow -up assessments, 
further diagnostic investigation, etc.). 
If the clinically significant laboratory abnormality is a sign of a  disease or syndrome (e.g. , 
increased alkaline phosphatase and bilirubin associated  with cholecystitis ), only the diagnosis 
(e.g., cholecystitis) needs to be recorded on the eCRF . 
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, the 
abnormality itself should be recorded as an AE or SAE on the eCRF.  If the laboratory 
abnormality can be characterized by a precise clinical term, the clinical term should be 
recorded as the AE or SAE.  For example, an elevated serum potassium level of 7.0  mEq/L 
should be recorded as “hyperkalemia” . 
Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedly recorded as AEs or SAEs on the Adverse  Event eCRF, unless their 
severity, seriousness, or etiology changes.  
10.6. Discontinuation due to Adverse Events  
Any subject who experiences an AE , serious or nonserious , may have study drug 
discontinued at any time at the discretion of the investigator. The AE(s) should be noted on 
the appropriate eCRFs and the subject’s progress should be followed until the AE is resolved 
or stabilized  as determined by the in vestigator. The Sponsor’ Medical Director and the CRO  
medical monitor must be notified. If the AE relates to overdose of study treatment, the 
Investigator’s Brochure should be consulted for details of any specific actions to be t aken.  
Subjects sho uld return to the study to complete assessments as outl ined in Section 6 . 
10.7. Reporting Serious Adverse Events  and Adverse Events of Special Interest  
SAEs /AESIs  occurring in this study will be reported  to the CRO’s Drug Safety Department 
within 24  hours of the investigator, designee, or site personnel’s knowledge of the event.  The 
SAE /AESI  will be reported by completing the SAE /AESI  eCRF in  the EDC system.  
In the event that the EDC system is not ava ilable, a paper SAE /AESI  report form  must be 
submitted  to the CRO’s Drug Safety Department ( drugsafety@wwctrials.com or faxed to 
1-866-387-5539 ) within 24  hours of becoming aware of the event.  The Principal Investigator 
or designee must complete the SAE /AESI  eCRF page as soon as the EDC system becomes 
available.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 58 
 
CONFIDENTIAL  
 Follow -up reports must be submitted in a timely fashion as additional information becomes 
available.  
The I nvestigator is responsible for notifying the Institutional Review Board (IRB) or 
Independent Eth ics Committees (IEC) in accordance with local regulations, of all SAEs.  The 
Sponsor  or designee may request additional source documentation pertaining to the SAE 
from the investigational site.  If a subject is permanently withdrawn from the study due to a n 
SAE, this information must be included in the initial or fo llow-up SAE report in the eCRF . 
Properly anonymized and de -identified documents (e.g. hospital discharge summaries, 
autopsy reports, and/or death certificates) as available will be provided to the CRO’s Drug 
Safety Department for all reported SAEs /AESIs . 
10.8. Choosing Adverse Event Terms  
Whenever possible, reported event terms for AEs (including SAEs) should be the names of 
medical events, not lists of symptoms or event outcomes.  Below are some examples of terms 
to avoid and more accurate alternatives.  
Examples of Terms to Avoid  Examples of More Accurate Terms  
Death (this is an outcome)  Fatal myocardial infarction (best choice)  
Death due to unknown cause, autopsy results 
pending (if no other information is available)  
Hospitalized (this is a serious criterion)  Myocardial infarction (best choice)  
Hospitalized with chest pain, rule out myocardial 
infarction (if no other information is available)  
Chest pain, shortness of breath, 
diaphoresis, anxiety, left a rm pain  Myocardial infarction (best choice)  
Hospitalized, rule out myocardial infarction (if no 
other information is available)  
10.9. Pregnancy  
Pregnancies occurring in a female subject or in a male subject’s partner while enrolled in this 
clinical study throug h 3 months after the last dose of study drug administ ration , must be 
reported on a Pregnancy Monitoring Form and sent to the CRO’s Drug Safety Department 
within 24 hours of the investigator, designee, or site personnel  learning of the pregnancy  
(refer to  Section  10.5). 
If a subject becomes pregnant while taking study drug, the study treatment will be 
immediately discontinued and the pregnancy must be reported within 24 hours.  The 
investigator will discuss the risks and concerns of investigational drug exposure  to a 
developing fetus and counsel the subject and/or pregnant partner (or ensure such counselling 
is provided).  
An uncomplicated pregnancy will not be considered an AE or SAE; however, all pregnancies 
will be followed through birth and 3 months post -delivery . 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 59 
 
CONFIDENTIAL  
 Any congenital abnormalities in the offspring of a subject who received investigational 
product will be reported as an SAE. The outcome of any pregnancy  and the presence or 
absence of any congenital abnormality will be recorded in the source documentation and 
reported to the CRO’s Drug Safety Department.  
The investigator will complete a Pregnancy Monitoring  Form and report the information 
regarding the pregnancy, outcome, and status of the newborn, as appropriate.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 60 
 
CONFIDENTIAL  
 11. DATA ANALYSIS AND STATIST ICAL PLANS  
Details of all planned analyses will be specified in a separate  statistical analysis plan.  
The study data will be reporte d using summary tables, figures  and data listings.  Continuous 
variables will be summarized  using mean, standard  deviation (SD), coefficient of variation 
(CV%, as appropriate), median, minimum, maximum, and, as appropriate, geometric mean.  
Categorical variables will be summarized  by presenting the number (frequency) and 
percentage in each category.  
Data from Parts A and B of the study will be pooled across the common treatment arms, i.e. , 
GBT440 60 0 mg  and placebo arms.  
11.1. Sample Size  
The sample size in this  initial study  was not selected based on statistical considerations but to 
determine preliminary safety, to lerability, PK, laboratory and clinical effects of GBT440 in 
IPF subject s.  
The study will enrol l approximately 33 subjects : approximately 18 subjects in Part A and 
approximately 15 subjects in Part B.  
11.2. Populations for Analysis  
The following populations will be considered in the analysis of data for this study. 
Assignment or exclusion of subjects from the analysis populations will be performed prior to 
study unblinding . 
• Safety population : All subjects who receive any amount of study medication will be 
included in the safety population. Subjects will be analyzed based on medication 
received. This is the primary population for all safety analyses performed for this 
study.  
• Efficacy evaluable population : All randomized subjects who received at least 15 days 
of study drug treatment will be included in the Efficacy evaluable population.  The 
Efficacy evaluable population will be used for analysis of all secondary and 
exploratory efficacy endpoints, and subjects will be analyzed as treated.  
• PK population : All subje cts who receive investigational treatment and provide 
adequate data to evalu ate the relevant PK parameter.  
11.2.1.  Primary Endpoint  
The primary endpoint for this study is the safety and tolerability of GBT440.  
Analysis will be based on data from all subjects  who were randomized and received at least 
one dose of study drug. Safety will be assessed by AEs, laboratory evaluations, vital signs 
and ECGs. Data from these subjects will be used for analysis of all baseline demographics 
and safety summaries.  
11.2.2.  Secondary end points  
Analysis of data for secondary efficacy endpoints will be based on all randomized subjects 
who received  at least 15 days of study drug treatment .  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 61 
 
CONFIDENTIAL  
 The treatment group for these analyses will be based on the treatme nt received  at 
randomization.  
11.2.3.  Pharmacokinetics  
Analysis of data for PK will be based on data from all subjects who received at least 1 dose 
of GBT440 and have sufficient PK data to derive at least 1 PK parameter . 
If any subjects are found  to be noncompliant with respect to dosing or have incomplete data, 
protocol violations, or clinical events that affect PK, a decision will be made on a case -by-
case basis as to their inclusion in the analysis.  Subjects in this population will be used for all 
PK summaries.  
11.3. Analyses  
Demographic and baseline characteristics, primary and secondary endpoints, and safety 
parameters will be summarized using descriptive statistics  and presented in individual 
listings.  
AEs will be reported by severity and relatedne ss to study treatment and classified according 
to the current version of  MedDRA.  
11.3.1.  Safety Data  
Safety data analysis will be performed on all randomized subjects who have received at least 
1 dose of study drug.  Individual and summary blood pressures, heart ra te, ECG parameters, 
exercise testing endpoints and clinical laboratory data (hematology, serum biochemistry and 
coagulation) will be summarized . 
For the laboratory safety data, out of range values will be flagged in the data listings and a 
list of clinical ly significantly abnormal values will be presented.  
Adverse events and medical history will be tabulated and summarized according to the 
current version of MedDRA.  
11.3.2.  Efficacy Data  
For secondary and exploratory endpoints, binary data will be analyzed  via Fish er’s exact test. 
Data for other endpoints will be analyzed  with Wilcoxon’s test  or analysis of covariance 
(ANCOVA) with baseline value as covariate . Full details of analysis methods , including how 
missing data will be handled,  will be provided in the SAP which will be finalized prior to 
study unblinding .  
11.3.3.  PK Data  
A listing of PK sample collection times as well as derived sampling time deviations will be 
provided.  A subject listing of all concentration -time data for  each treatment, and study day 
will be pr esented.  PK variables will be summarized using appropriate descriptive statistics 
(e.g., n, mean, SD, CV%, minimum, median, and maximum, and/or geometric mean) by part, 
dose, and study day.   
Graphical presentations of key PK parameters and concentrations w ill be used as appropriate.  
Figures of individual concentrations  versus time will be presented by subject.   
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 62 
 
CONFIDENTIAL  
 Steady state of GBT440 will be assessed graphically.  
Exploration of exposure -response relationships of GBT440 to  exploratory efficacy data, and 
safety data (described below) will be performed as data permits.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 63 
 
CONFIDENTIAL  
 12. REGULATORY, ETHICAL AND LEGAL OBLIGATIONS  
12.1. Ethical Consideration  
It is the responsibility of the Investigator to assure that the study is conducted in accordance 
with current country and loca l regulations, FDA, ICH GCP, the Declaration of Helsinki, and 
Good Clinical Practice . 
The study will be conducted according to the protocol, and guidelines established by the ICH 
for GCP in clinical trials.  
12.2. Institutional Review Board (IRB)  and Regulatory Appro val 
The Investigator must inform, and obtain approval from, the IRB/IEC  for the conduct of the 
study at named sites, for the protocol, the Subject Informed Consent Form, and any other 
written information that will be provided to the subjects and any advert isements that will be 
used.  Written approval must be obtained prior to recruitment of subjects into the study and 
shipment of investigational drug.  
Proposed amendments to the protocol and aforementioned documents must be discussed 
between  the Sponsor and C RO, and then submitted to the IRB/IEC  for approval.  
Amendments may be implemented only after a copy of the local IRB approval letter has been 
transmitted to the Sponsor.  Amendments that are intended  to eliminate an apparent 
immediate hazard to subjects may be implemented prior to receiving Sponsor or IRB/IEC  
approval.  However, in this case, approval must be obtained as soon as possible after 
implementation.  
The Investigator will be responsible for en suring that an annual update is sent to the IRB/IEC  
to facilitate their continuing review of the trial (if needed) and that the IRB/IEC  is informed 
about the end of the study.  Copies of the update, subsequent approvals and final letter must 
be sent to the Sponsor.  
12.3. Insurance and Financial Disclosure  
The Sponsor has subscribed to an insurance policy covering, in its terms and provisions, its 
legal liability for injuries caused to participating persons and arising out of this research 
performed strictly in acc ordance with the scientific protocol as well as with applicable law 
and professional standards.   
Financial Disclosure statements will be handled in a separate agreement apart from the 
protocol, kept on file and submitted as applicable with any subsequent license application.  
12.4. Essential Documentation Requirements  
The Sponsor will collect from the investigational site the required essential regulatory 
documents per ICH guidance prior to GBT440  shipment to the site . 
12.5. Informed Consent  
It is the Investigator’s re sponsibility to obtain written informed consent from the subject after 
adequate explanation of the objectives, methods, anticipated benefits, and potential hazards 
of the study and before any study procedures are commenced.  The subject should be given a 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 64 
 
CONFIDENTIAL  
 copy of the Informed Consent  Form (ICF)  in their native language.  The informed  consent 
process should be recorded in the source documentation.  The original copy of the signed and 
dated informed consent must be retained in the institution’s records, and is su bject to 
inspection by representatives of the Sponsor, or representatives from regulatory agencies.  
12.6. Confidentiality  
The Investigator must ensure that the subject’s privacy is maintained.  On the CRF or other 
documents submitted to the Sponsor, subjects will  be identified by a subject study number 
only.  Documents that are not submitted to the Sponsor (e.g., signed informed consent form) 
should be kept in a strictly confidential file by the Investigator.  
The Investigator shall permit authorized representatives  of the Sponsor, regulatory agencies 
and IRBs  to review the portion of the subject’s medical record that is directly related to the 
study.  As part of the required content of informed consent, the subject must be informed that 
his/her records will be review ed in this manner.  
12.7. Trial Documentation and Data Storage  
The Investigator must retain a comprehensive and centralized filing system of all trial -related 
documentation that is suitable for inspection by the Sponsor and representatives of regulatory 
authoriti es. 
The Investigator must retain essential documents until at least 2 years after the last approval 
of a marketing application.  Subject files and other source data (including copies of protocols, 
original reports of test results, investigational drug dispe nsing logs, correspondence, records 
of informed consent, and other documents pertaining to the conduct of the trial) must be kept 
for the maximum period of time permitted by the institution.  Documents should be stored in 
such a way that they can be accesse d/data retrieved at a later date.  Consideration should be 
given to security and environmental risks.  
No trial document will be destroyed without prior written agreement between the Sponsor 
and the Investigator.  Should the Investigator wish to assign the tr ial records to another party 
or move them to another location, written agreement must be obtained from the Sponsor.  
12.8. Study Record Retention  
In accordance with 21 CFR 312.62(c), the investigators will retain records required to be 
maintained under this part for a period of 2 years following the date a marketing application 
is approved for the drug for the indication for which it is being investigated. If no application 
is to be filed or if the application is not approved for such indication, the investigator will 
retain these records until 2 years after the investigation is discontinued and the US FDA or 
applicable regulatory authorities are notified.  
The investigators must retain protocols, amendments, IRB/IEC approvals, copies of the Form 
FDA 1572, signed an d dated consent forms, medical records, eCRFs, drug accountability 
records, all correspondence and any other documents pertainin g to the conduct of the study.  
If the Principal Investigator moves, withdraws from an investigation or retires, the 
responsibility for maintaining the records may be transferred to another person who will 
accept responsibility.  Notice of transfer must be mad e to and agreed by the Sponso r. 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 65 
 
CONFIDENTIAL  
 12.9. Disclosure of Information  
Information concerning the study, patent applications, processes, scientific data or other 
pertinent information is confidential and remains the property of the Sponsor.  The 
Investigator may use this information for the purpose s of the study only.  
It is understood by the Investigator that the Sponsor will use information developed in this 
clinical study in connection with the development of GBT440  and, therefore, may disclose it 
as required to other clinical investigators and to  regulatory agencies.  In order to allow the use 
of the information derived from this clinical study, the Investigator understands that he/she 
has an obligation to provide complete test results and all data developed during this study to 
the Sponsor.  
Verbal  or written discussion of results prior to study completion and full reporting should 
only be undertaken with written consent from the Sponsor.  
12.9.1.  Publication  
The Sponsor intends  to publish the results of the study as a whole once all subjects have 
completed the study and the study has been analyzed.  
The I nvestigator may not submit the results of the study for publication without the prior 
consent of the Sponsor.  
The Investigator or the Sponsor may not submit for publication or present the results of this 
study without allowing each of the other parties adequate time to review and comment on the 
pre-publication manuscript.   
Authorship will be determined by mutual agreement and in line with the International 
Committee of Medical Journal Editors authorship requir ements.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 66 
 
CONFIDENTIAL  
 13. ADMINSTRATIVE OBLIGATIONS  
13.1. Source Data  
Original documents, data, records (e.g., clinic records, laboratory notes, memoranda, subject 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies or transcriptions certified after verification as being accurate and 
complete, microfiches, photographic negatives, microfilm or magnetic media, X -rays, subject 
files, and records kept at the pharmacy, at the laboratories, and at medico -technical 
departments involved in the clinical trial) and all relevant sections of the subject’s medical 
records and all other data collection made specific to this trial constitute source documents.  
The completed CRF is not a source document.  The Investigator/institution will permit trial -
related monitoring, audits, IRB review and regulatory inspection by providing direct access 
to source documents.  
13.2. Data Collection  
The investigator will be responsible for maintaining accurate and adequate case records 
(source documents) from wh ich data will be transcribed (or if electronically captured [EDC] 
source data, transferred) to CRFs designed to record data pertinent to this study.  All relevant 
observations and data related to the study will be so recorded.  This will include medical and 
medication history, physical examinations, a checklist of inclusion and exclusion criteria, 
investigational treatment administration, and a  record of sample collection, clinical 
assessments, AEs, and final evaluation. The clinical site Clinical Research As sociate (CRA) 
will review all CRFs and compare data to that contained in clinic notes and subjects’ source 
documents/medical records.  
Data collected for each  subject will be entered into the CRF.  The investigator will be 
responsible for the timeliness, com pleteness, and accuracy of the documentation entered into 
the CRFs.  
13.3. Monitoring  
It is understood that monitors, and any authorized personnel contracted to Sponsor may 
contact and visit the Investigator, and that they will be allowed to inspect the various r ecords 
of the trial on request (CRFs and other pertinent data), provided that subject confidentiality is 
maintained, and that the monitoring is conducted in accordance with local regulations.  
It is the monitor’s responsibility to inspect the CRFs at regula r intervals throughout the trial 
to verify adherence to the protocol, the completeness, accuracy and consistency of the data, 
and adherence to Good  Clinical Practice guidelines.  
The Investigator agrees to co -operate with the monitor to ensure that any prob lems detected 
during the course of these monitoring visits are resolved.  
13.4. Quality Control and Quality Assurance  
Quality Control will be performed according to the Sponsor  or Sponsor’s designee internal 
procedures.  A Quality Assurance representative of the Sponsor may audit the study.  All 
necessary data and documents will be made available for inspection.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 67 
 
CONFIDENTIAL  
 14. REFERENCES  
American Thoracic Society statement: guidelines for the six -minute walk test. Am J Respir  
Crit Care Med 2002; 166(1):111 -117. 
American Thoracic Society. 2005. Pulmonary Fun ction Laboratory Management and 
American Thoracic Society/ American College of Chest Physicians statement on 
cardiopulmonary exercise testing.  Am J Respir  Crit Care Med 2003;167(2):211 -277. 
Eaton JW. Extreme altitude: Protective  effect of increased hemoglobin -oxygen. Science , 183 
(February 1974).  
Eaton T, Lewis C, Young P, Kennedy Y, Garrett JE, et al.  Long -term oxygen therapy 
improves health -related quality of life.  Respir Med. 2004; 98:285 -293 
Hebbel RP, Eaton JW, Kronenberg RS , Zanjani ED.  Adaptation to altitude in subjects with 
high hemoglobin oxygen affinity.; J Clin Invest 1978; 62 (3): 593 -600. 
Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, et al. An official European 
Respiratory Society/American Thoracic Society te chnical standard : field walking tests in 
chronic respiratory disease. Eur Respir J 2014;44: 1428 -1446  
King TE, Bradford WZ, Castro -Bernardini S, et al.  A Phase 3 trial of pirfenidone in patients 
with idiopathic pulmonary fibrosis. NEJM 2014; 370 (22); 2083 -2092.  
King TE, Tooze JA, Schwarz MI, et al.  Predicting survival in idiopathic pulmonary fibrosis: 
scoring system and survival model.  Am J Respir  Crit Care Med 2001;164: 1171 -1181.  
Lehrer -Graiwer J, Howard J, Hemmaway CJ, Awogbade M, Telfer P, Layton M, et  al. 
GBT440, a potent anti -sickling hemoglobin modifier reduces hemolysis, improves anemia 
and nearly eliminates sickle cells in peripheral blood of patients with sickle cell disease. Oral 
presentation: American Society of Hematology Annual Meeting; Orland o, FL. 2015.  
Michaelson JE, Aguayo SM, Roman J.  Idiopathic pulmonary fibrosis; a practical approach 
for diagnosis and management. Chest 2000;118:788 -794. 
Nicholson AG, Colby TV, du Bois RM, et al.  The prognostic significance of the histologic 
pattern of in terstitial pneumonia in patients presenting with the clinical entity of cryptogenic 
fibrosing  alveolitis.  Am J Respir  Crit Care Med 2000;162:2213 -2217  
Olson AL, Swigris JJ. Idiopathic pulmonary fibrosis; diagnosis and epidemiology . Clin Chest 
Med 2012; 33:  41-50. 
Procedure Manual [Manual on CD -ROM]. 2nd ed.  
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic 
pulmonary  fibrosis: evidence -based guidelines for diagnosis and management. Am J Respir  
Crit Care Med  2011;183:788 -824. 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 68 
 
CONFIDENTIAL  
 Raghu G, Rochwerg B, Zhang Y. An official ATS/ERS/JRS/ALAT clinical practice 
guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice 
guideline.  Am J Respir  Crit Care Med 2015; 192 (2): e3 -e19. 
Raghu G, Weycker D, Edelsberg, et al.  Incidence and prevalence of Idiopathic pulmonary 
fibrosis. Am J Respir  Crit Care Med 2006;174: 810 -816. 
Richeldi  L, du Bois Rm, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic 
pulmonary fibrosis.  NEJM 2014: 3 70 (22): 2071 -2082.  
Yalcin O, Cabrales P. Increased hemoglobin O2 affinity protects during acute hypoxia. Am J 
Physiol Heart Circ Physiol. 2012 Aug 1;303(3):H271 -81. 
 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 69 
 
CONFIDENTIAL  
 15. APPENDICES
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016   Page 70 
 
CONFIDENTIAL  
 APPENDIX  A SCHEDULE OF STUDY AS SESSMENTS  
Study Day  (Window)  Screeninga  Treatment Period  Follow -up Visit s 
Day -21 to 
Day -1 Day 1 Day 2 Day 8  
(+/- 2) Day 15  
(+/- 2) Day 28 
(+/- 2) Day 29  
(+3) Day 45b 
(+/- 3) Day 58 
(+/- 3) 
Visit  1 2 3 4 5 6 7 8 9 
Informed Consentc X         
Eligibility Assessment  X X        
Demographic data  X Xd        
Medical History  and baseline conditions  X Xd        
Concomitant Medications  X X X X X X X X X 
Complete Physical Examinatione X        X 
Limited Physical Examinationf  X  X X X X X  
Height  X         
Weight  X     X    
Vital Signsg X X X X X X X X X 
SpO 2h X X X X X X X X X 
ECG (12 -lead)i X   X X X  X X 
Adverse Eventsj Xj X X X X X X X X 
Serum Pregnancy Test (females only)k X         
Urine Pregnancy Test (females only)l    X X X  X X 
Hematology X   X X X  X X 
Serum Chemistry X   X X X  X X 
Urinalysis X    X X  X X 
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016   Page 71 
 
CONFIDENTIAL  
 Study Day  (Window)  Screeninga  Treatment Period  Follow -up Visit s 
Day -21 to 
Day -1 Day 1 Day 2 Day 8  
(+/- 2) Day 15  
(+/- 2) Day 28 
(+/- 2) Day 29  
(+3) Day 45b 
(+/- 3) Day 58 
(+/- 3) 
Coagulation Panel (PT, PTT, INR)  X     X    
Serum Erythropoietin  X     X  X X 
Serology (Hepatitis A, B, C, and HIV)  X         
PK Blood Samplesm  X X X X X  X X 
Spirometry and DL CO X     X   X 
6 Minute Walk Testn Xn    X X   X 
Cardiopulmonary Exercise Testingn    X    X   
Randomization (IxRS)   X        
Study Drug Dispensing to Subjecto   X X X     
Study Drug Administration at sitep  X X X X X    
St. George’s Respiratory Questionnaireq  X    X   X 
UCSD Shortness of Breath Questionnaireq  X  X X X  X X 
ATAQ -IPF Symptomsq  X  X X X  X X 
ATAQ -IPF Impactsq  X  X X X  X X 
End of Study  Questionnairer         X 
Cough Visual Analogue Scaleq  X  X X X  X X 
Abbreviations : ATAQ  = A Tool to Assess Quality of Life; DL CO = lung diffusing capacity  measured using carbon monoxide ; ECG =  electrocardiogram ; 
HIV = human immunodeficiency virus; INR =  international normalized ratio; PK =  pharm acokinetic; PRO =  patient reported outcome; PT =  prothrombin time; 
PTT =  partial thromboplastin time ; SGRQ =  St. Geo rge’s Respiratory Questionnaire;  SpO 2 = oxygen saturatio n measured by pulse oximetry ; UCSD =  University 
of California San Diego . 
Note:  All assessments should be performed within the number of days ( Window) as indicated for each schedule d visit day. All assessments should be performed  
prior to receiving study drug  during the treatment period unless otherwise indicated . SGRQ, ATAQ, UCSD, Cough VAS should be performed before all other 
non-PRO assessments, followed by 12 -lead ECG and then vital sign assessments.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016   Page 72 
 
CONFIDENTIAL  
 a All screening evaluations must be completed and reviewed prior to Day 1 ( Visit 2) to confirm the subject meets all eligibility criteria prior to randomization 
to the treatment period . In cases when the screening 6MWT is done more than 7 days prior to Visit 2, it must be repeated, u p and through Day 1, prior to any 
Day 1 assessments.  
b All subjects  who discontinue study or study drug prior to study completion and who are unwilling or unable to complete the remaining scheduled visits 
should return to the study site to complete all Day 4 5 (Visit 8 ) assessments ( refer to  Section 6 )  
c Written informed consent must be obtained and documented prior  to performing any study -specific screening procedure  
d Demographics, medical history and baseline conditions obtained at screening should be reviewed again at this visit and any changes since screening updated 
in the eCRF  
e Includes evaluation of the head, eyes, ears, nose and throat and cardiovascular, respiratory, musculoskeletal, gastrointestin al, neurological, dermatologic  
systems . No rectal or pelvic examination is required . Record any observed abnormalities in the eCRF. At subsequent visits record new or worsened clinically 
significant findings on the eCRF  
f Perform a limited, symptom -directed examination as clinically indi cated. Record new or worsened clinically significant findings in the eCRF . 
g Includes heart rate, respiratory rate, systolic and diastolic blood pressure and temperature measured whilst in a semi -recumbent or supine position  and resting 
for at least 5 minute s.  
h Performed while the subject is seated an d resting for at least 5minutes . 
i Perform 12 -lead ECG in triplicate ; three separate tracings with approximately 1 minute betwe en each tracing, after resting in a semi -recumbent or  supine 
position for at least 5 mi nutes.  
j After informed consent but prior to randomization only serious adverse events (SAEs) resulting from a protocol -mandated intervention should be reported. 
After randomization,  all adverse events will be reported until study completion  (Day 58) .  
k Perfo rmed for all female patients who are not post -menopausal or surgically sterile  
l If a urine pregnancy test is positive the result must be confirmed with a serum pregnancy test  
m PK blood samples  during the treatment period should be collected on Days 1 and 28 : Pre-dose and 2 hours post dose (+/- 15 minutes) ; Day 2: 24 hours 
(+/-2 hours) after the Day 1 dose and prior to receiving the Day 2 dose ; Days 8 and 15: Pre-dose only.  
n Instructions for per -protocol performance of the 6-minute  walk  (and Borg dyspnea scal e) and cardio -pulmonary exercise tests  are provided in the procedure 
manual.  Note:  The baseline  6MWT performed during screening must  be performed within 7 days  of the Day 1 visit.  
o An unblinded study pharmacist will prepare daily doses of study drug , dispensed into 30  mL high -density polyethylene (HDPE) bottles. Each bottle (or dose) 
is packaged individually with 3 capsules of active or placebo or both specific to each subject’s assigned treatment group. Subjects who have their dose 
modified during the  study must return to the site to have the modified dose of study drug dispensed by the unblinded pharmacist.  
p Subjects should not administer study drug  on the morning of these study visits. Study drug will be administered by the study staff after completio n of all 
pre-dose assessments.   
q The SGRQ,  ATAQ and UCSD questionnaires  and cough VAS should be self -administered  by the subject,  using the paper forms provided by the Sponsor 
prior to all other non -PRO assessments and before the patient receives any diseas e-status information during that assessment. ATAQ questionnaires should 
be administered to subjects enrolled in Part B of the study.  
r The End of Study Q uestionnaire should  be administered to subjects enrolled in Part B of the study.  
Protocol Number GBT440 -006  Global Blood Therapeutics  
Final  21 December 2016  Amendment 3  Page 73 
 
CONFIDENTIAL  
 APPENDIX  B STRONG INDUCERS  OF CYP  ISOENZYMES  
 
CYP  Enzymes  Medications  
CYP3A4/3A5  Avasimibe, carbamazepine, phenytoin, rifampin, St.  John’s 
wort 
CYP2B6, CYP2C9, CYP2C19  Currently no known inducers  
 
Please note the following: This is not an exhaustive list. For an updated list, refer to the following link: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm08
0499.htm . 
   
 
 
 